WHO Drug Information, Vol. 24, No. 1, 2010                                                Recommended INN: List 63



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 63
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/ERC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in Cumulative List
No. 13, 2009 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 63
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/ERC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans
la Liste récapitulative No. 13, 2009 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 63
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/ERC/1)], se comunica por el presente
anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes
Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes
Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en
farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran
reunidas en Cumulative List No. 13, 2009 (disponible sólo en CD-ROM).


                                                                                                                  41
Recommended INN: List 63                                                            WHO Drug Information, Vol. 24, No. 1, 2010




 Latin, English, French, Spanish:

 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 acidum obeticholicum
 obeticholic acid                          6α-ethyl-3α,7α-dihydroxy-5β-cholan-24-oic acid

 acide obéticholique                       acide 6α-éthyl-3α,7α-dihydroxy-5β-cholan-24-oïque

 ácido obeticólico                         ácido 6α-etil-3α,7α-dihidroxi-5β-colan-24-oico

                                           C26H44O4

                                                                           H3C      H
                                                                           CH3             CO2H
                                                                                     H
                                                              CH3      H        H

                                                                   H       H
                                            HO                             OH
                                                     H        H        H
                                                                       CH3

 acidum tiomolibdicum
 tiomolibdic acid                          dihydrogen(tetrasulfidomolybdate)

 acide tiomolibdique                       tétrasulfidomolybdate d'hydrogène

 ácido tiomolíbdico                        dihidrógeno(tetrasulfuromolibdato)

                                           H2MoS4

                                                 S        S

                                                     Mo
                                            HS                SH

 afacifenacinum
 afacifenacin                              (4S)-4-phenyl-3-(1-{[3-(trifluoromethoxy)phenyl]methyl}piperidin-
                                           4-yl)-3,4-dihydroquinazolin-2(1H)-one

 afacifénacine                             (4S)-4-phényl-3-(1-{[3-(trifuorométhoxy)phényl]méthyl}pipéridin-4-yl)-
                                           3,4-dihydroquinazolin-2(1H)-one

 afacifenacina                             (4S)-4-fenil-3-(1-{[3-(trifluorometoxi)fenil]metil}piperidin-4-il)-
                                           3,4-dihidroquinazolin-2(1H)-ona




42
WHO Drug Information, Vol. 24, No. 1, 2010                                              Recommended INN: List 63




                                             C27H26F3N3O2

                                                       H
                                                       N        O
                                                                           OCF3
                                                           N

                                                           H        N




 afegostatum
 afegostat                                   (3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol

 afégostat                                   (3R,4R,5R)-5-(hydroxyméthyl)pipéridine-3,4-diol

 afegostat                                   (3R,4R,5R)-5-(hidroximetil)piperidina-3,4-diol

                                             C6H13NO3

                                                   H
                                             HO
                                                           NH
                                               H
                                             HO
                                                           H
                                                           OH

 aganirsenum
 aganirsen                                   all-P-ambo-thymidylyl-(3′ →5′ )-2′ -deoxy-P-thioadenylyl-(3′ →5′ )-P-
                                             thiothymidylyl-(3′ →5′ )-2′ -deoxy-P-thiocytidylyl-(3′ →5′ )-2′ -deoxy-
                                             P-thiocytidylyl-(3′ →5′ )-2′ -deoxy-P-thioguanylyl-(3′ →5′ )-2′ -deoxy-
                                             P-thioguanylyl-(3′ →5′ )-2′ -deoxy-P-thioadenylyl-(3′ →5′ )-2′ -deoxy-
                                             P-thioguanylyl-(3′ →5′ )-2′ -deoxy-P-thioguanylyl-(3′ →5′ )-2′ -deoxy-
                                             P-thioguanylyl-(3′ →5′ )-2′ -deoxy-P-thiocytidylyl-(3′ →5′ )-P-
                                             thiothymidylyl-(3′ →5′ )-2′ -deoxy-P-thiocytidylyl-(3′ →5′ )-2′ -deoxy-
                                             P-thioguanylyl-(3′ →5′ )-2′ -deoxy-P-thiocytidylyl-(3′ →5′ )-2′ -deoxy-
                                             P-thiocytidylyl-(3′ →5′ )-2′ -deoxy-P-thioadenylyl-(3′ →5′ )-P-
                                             thiothymidylyl-(3′ →5′ )-2′ -deoxy-P-thioguanylyl-(3′ →5′ )-2′ -deoxy-
                                             P-thiocytidylyl-(3′ →5′ )-P-thiothymidylyl-(3′ →5′ )-2′ -deoxy-P-
                                             thioguanylyl-(3′ →5′ )-2′ -deoxy-P-thiocytidylyl-(3′ →5′ )-P-
                                             thiothymidine

 aganirsen                                   tout-P-ambo-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-
                                             (3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-
                                             déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                                             déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-
                                             déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                                             déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-
                                             thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                                             thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                                             thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-
                                             (3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                                             (3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                                             déoxy-P-thiocytidylyl-(3'→5')-thymidine




                                                                                                                       43
Recommended INN: List 63                                    WHO Drug Information, Vol. 24, No. 1, 2010


 aganirsén                 todo-P-ambo-timidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-
                           tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-
                           (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-
                           2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-
                           desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-
                           P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-
                           2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-
                           P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-
                           (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-
                           P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-
                           tiocitidilil-(3'→5')-P-tiotimidina

                           C242H307N91O127P24S24

                           (3'-5')d(P-thio)(T-A-T-C-C-G-G-A-G-G-G-C-T-C-G-C-C-A-T-G-C-T-
                           G-C-T)

 albitiazolii bromidum
 albitiazolium bromide     3,3′-(dodecan-1,12-diyl)bis[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-
                           3-ium] dibromide

 bromure d'albitiazolium   dibromure de 3,3'-(dodécane-1,12-diyl)bis[5-(2-hydroxyéthyl)-
                           4-méthyl-1,3-thiazol-3-ium]

 bromuro de albitiazolio   dibromuro de 3,3′-(dodecan-1,12-diil)bis[5-(2-hidroxietil)-4-metil-
                           1,3-tiazol-3-io]

                           C24H42Br2N2O2S2

                                                                                H3 C            OH
                                            Br
                                                                                            S
                                                                                       N
                                            N
                                    S
                                                                                       Br
                           HO                    CH3


 arhalofenatum
 arhalofenate              2-(acetamido)ethyl (2R)-2-(4-chlorophenyl)-
                           2-[3-(trifluoromethyl)phenoxy]acetate

 arhalofénate              (2R)-2-(4-chlorophényl)-2-[3-(trifluorométhyl)phénoxy]acétate de
                           2-(acétylamino)éthyle

 arhalofenato              (2R)-2-(4-clorofenil)-2-[3-(trifluorometil)fenoxi]acetato de
                           2-(acetamido)etilo

                           C19H17ClF3NO4

                                                 O
                                                             H
                                        O                    N       CH3
                                                     O
                                        H                        O

                              CF3
                                                       Cl




44
WHO Drug Information, Vol. 24, No. 1, 2010                                                         Recommended INN: List 63


 atalurenum
 ataluren                                    3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

 ataluren                                    acide 3-[5-(2-fluorophényl)-1,2,4-oxadiazol-3-yl]benzoïque

 atalureno                                   ácido 3-[5-(2-fluorofenil)-1,2,4-oxadiazol-3-il]benzoico

                                             C15H9FN2O3



                                                      N
                                                                          CO2H
                                                  O
                                                          N


                                                          F


 atiratecanum
 atiratecan                                  (9S)-9-ethyl-10,13-dioxo-1-pentyl-9,10,13,15-tetrahydro-1H,12H-
                                             pyrano[3′′,4′′:6′,7′]indolizino[2′,1′:5,6]pyrido[4,3,2-de]quinazolin-9-yl
                                             glycyl-N-methylglycinate

 atiratécan                                  glycyl-N-méthylglycinate de (9S)-9-éthyl-10,13-dioxo-1-pentyl-
                                             9,10,13,15-tétrahydro-1H,12H-
                                             pyrano[3'',4'':6',7']indolizino[2',1':5,6]pyrido[4,3,2-de]quinazolin-9-yle

 atiratecán                                  glicil-N-metilglicinato de (9S)-9-etil-10,13-dioxo-1-pentil-9,10,13,15-
                                             tetrahidro-1H,12H-pirano[3′′,4′′:6′,7′]indolizino[2′,1′:5,6]pirido[4,3,2-
                                             de]quinazolin-9-ilo

                                             C31H34N6O6
                                                                CH3

                                                                    O

                                                  N             N                  O
                                             N
                                                                                       O       O
                                                          N                    O                   NH2
                                                                          CH3              N
                                                                                   O       CH3

 bardoxolonum
 bardoxolone                                 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid

 bardoxolone                                 acide 2-cyano-3,12-dioxooléana-1,9(11)-dién-28-oïque

 bardoxolona                                 ácido 2-ciano-3,12-dioxooleana-1,9(11)-dien-28-oico

                                             C31H34N6O6

                                                                          H3C      CH3

                                                                O
                                                                      H

                                                          CH3   CH3        H       CO2H
                                             NC
                                                                      CH3
                                               O
                                               H3C      H
                                                      CH3


                                                                                                                          45
Recommended INN: List 63                               WHO Drug Information, Vol. 24, No. 1, 2010


 beclanorsenum
 beclanorsen               all-P-ambo-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-2'-
                           O,4'-C-methylene -P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                           (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                           (3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-
                           (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                           deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-5-
                           methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-5-methyl-2'-O,4'-
                           C-methylene-P-thiocytidylyl-(3'→5')-2'-deoxyadenosine

 béclanorsen               tout-P-ambo-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-5-
                           méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-2'-déoxy-P-
                           thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                           thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-déoxy-P-
                           thioadénylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                           thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-
                           thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                           thioguanylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-
                           (3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-
                           déoxyadénosine

 beclanorsén               todo-P-ambo-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-O,4'-
                           C-metileno-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-
                           desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-
                           tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-
                           tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-
                           2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-
                           P-tioguanilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-5-
                           metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxiadenosina

                           C159H201N58O82P15S15

                           (3'-5')d(P-thio)(mrC-rT-C-C-C-A-A-C-G-T-G-C-G-mrC-mrC-A)
                            rT               H          mrC
                                       O       N   O                   O       N   NH2
                             OH                              OH
                                   O       N                       O       N
                                                   CH3                             CH3
                           H2C                             H2C
                                           H                               H
                              HO       O                      HO       O

 bixalomerum
 bixalomer                 cross linked polymer made of N,N,N',N'-tetrakis(3-
                           aminopropyl)butane-1,4-diamine N substituted by bivalent
                           substituent groups 2-hydroxypropane-1,2-diyl and
                           1-(hydroxymethyl)ethylene (x=20, 45≤y≤50)

 bixalomère                N,N,N',N'-tétrakis(3-aminopropyl)butane-1,4-diamine N substituée
                           par les groupes substituants divalents 2-hydroxypropane-1,2-diyle et
                           1-(hydroxyméthyl)éthylène pour former un polymère réticulé (x=20,
                           45≤y≤50)

 bixalómero                N,N,N',N'-tétrakis(3-aminopropil)butano-1,4-diamina N sustituida por
                           los grupos sustituyentes divalentes 2-hidroxipropano-1,2-diilo y
                           1-(hidroximetil)etileno para formar un polímero reticulado (x=20,
                           45≤y≤50)




46
WHO Drug Information, Vol. 24, No. 1, 2010                                                  Recommended INN: List 63




                                             (C16H36N6)x . (C3H6O)y

                                                                                        H
                                                                                        N
                                                                                            H
                                                                              N             N
                                                  N                  N
                                                  H
                                                      N
                                                      H                                             x

                                                           OH                     H2
                                                                         or       C
                                                                         ou            CH
                                                      C         C        o
                                                      H2        H2
                                                                                  HO
                                                                                                y




 briakinumabum #
 briakinumab                                 immunoglobulin G1-lambda, anti-[Homo sapiens interleukin 12 beta
                                             subunit (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40)], Homo
                                             sapiens monoclonal antibody;
                                             gamma1 heavy chain (1-445) [Homo sapiens VH (IGHV3-30*02
                                             (99.00%) -(IGHD)-IGHJ3*01) [8.8.8] (1-115) -IGHG1*03 R120>K
                                             (116-445)], (218-216')-disulfide with lambda light chain (1'-217')
                                             [Homo sapiens V-LAMBDA (IGLV1-44*01 (88.20%) -IGLJ2*01
                                             G120>T) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; (224-224'':227-
                                             227'')-bisdisulfide dimer

 briakinumab                                 immunoglobuline G1-lambda, anti-[Homo sapiens interleukine 12
                                             sous-unité bêta (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40)],
                                             Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-445) [Homo sapiens VH (IGHV3-30*02
                                             (99.00%) -(IGHD)-IGHJ3*01) [8.8.8] (1-115) -IGHG1*03 R120>K
                                             (116-445)], (218-216')-disulfure avec la chaîne légère kappa (1'-217')
                                             [Homo sapiens V-LAMBDA (IGLV1-44*01 (88.20%) -IGLJ2*01
                                             G120>T) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimère (224-
                                             224'':227-227'')-bisdisulfure

 briakinumab                                 inmunoglobulina G1-lambda, anti-[interleukina 12 subunidad beta
                                             (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40) de Homo sapiens],
                                             anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-445) [Homo sapiens VH (IGHV3-30*02
                                             (99.00%) -(IGHD)-IGHJ3*01) [8.8.8] (1-115) -IGHG1*03 R120>K
                                             (116-445)], (218-216')-disulfuro con la cadena ligera kappa (1'-217')
                                             [Homo sapiens V-LAMBDA (IGLV1-44*01 (88.20%) -IGLJ2*01
                                             G120>T) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dímero (224-
                                             224'':227-227'')-bisdisulfuro




                                                                                                                     47
Recommended INN: List 63                                    WHO Drug Information, Vol. 24, No. 1, 2010


                           C6376H9874N1722O1992S44

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVESGGG VVQPGRSLRL SCAASGFTFS                     SYGMHWVRQA    PGKGLEWVAF        50
                           IRYDGSNKYY ADSVKGRFTI SRDNSKNTLY                     LQMNSLRAED    TAVYYCKTHG       100
                           SHDNWGQGTM VTVSSASTKG PSVFPLAPSS                     KSTSGGTAAL    GCLVKDYFPE       150
                           PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL                     SSVVTVPSSS    LGTQTYICNV       200
                           NHKPSNTKVD KKVEPKSCDK THTCPPCPAP                     ELLGGPSVFL    FPPKPKDTLM       250
                           ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV                     EVHNAKTKPR    EEQYNSTYRV       300
                           VSVLTVLHQD WLNGKEYKCK VSNKALPAPI                     EKTISKAKGQ    PREPQVYTLP       350
                           PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE                     SNGQPENNYK    TTPPVLDSDG       400
                           SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL                     HNHYTQKSLS    LSPGK            445

                           Light chain / Chaîne légère / Cadena ligera
                           QSVLTQPPSV SGAPGQRVTI SCSGSRSNIG                     SNTVKWYQQL    PGTAPKLLIY 50
                           YNDQRPSGVP DRFSGSKSGT SASLAITGLQ                     AEDEADYYCQ    SYDRYTHPAL 100
                           LFGTGTKVTV LGQPKAAPSV TLFPPSSEEL                     QANKATLVCL    ISDFYPGAVT 150
                           VAWKADSSPV KAGVETTTPS KQSNNKYAAS                     SYLSLTPEQW    KSHRSYSCQV 200
                           THEGSTVEKT VAPTECS                                                            217

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        142-198       259-319  365-423
                                     22''-96'' 142''-198'' 259''-319'' 365''-423''
                           Intra-L 22'-89' 139'-198'
                                    22'''-89''' 139'''-198'''
                           Inter-H-L 218-216' 218''-216'''
                           Inter-H-H 224-224'' 227-227''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           295, 295''



 budiodaronum
 budiodarone               (2S)-butan-2-yl 2-(3-{4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl}-
                           1-benzofuran-2-yl)acetate

 budiodarone               2-(3-{4-[2-(diéthylamino)éthoxy]-3,5-diiodobenzoyl}-1-benzofuran-
                           2-yl)acétate de (2S)-butan-2-yl

 budiodarona               2-(3-{4-[2-(dietilamino)etoxi]-3,5-diiodobenzoil}-1-benzofuran-
                           2-il)acetato de (2S)-butan-2-ilo

                           C27H31I2NO5

                                              O
                               H3C H
                                                           O
                           H3C            O
                                                                            I               CH3
                                                  O
                                                                                        N       CH3
                                                                            O
                                                                    I



 burapitantum
 burapitant                2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluoromethyl)phenyl]acetyl}-
                           2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}piperidin-4-yl)-
                           2-methylpropanamide

 burapitant                2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluorométhyl)phényl]acétyl}-
                           2-(3,4-dichlorophényl)morpholin-2-yl]éthyl}pipéridin-4-yl)-
                           2-méthylpropanamide

 burapitant                2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluorometil)fenil]acetil}-
                           2-(3,4-diclorofenil)morfolin-2-il]etil}piperidin-4-il)-2-metilpropanamida




48
WHO Drug Information, Vol. 24, No. 1, 2010                                                Recommended INN: List 63


                                             C31H35Cl2F5N3O3

                                                                             Cl
                                                   H3C       CH3        Cl                 CF3
                                             H2N
                                                                                      O
                                                   O                N
                                                                                  N              CF3
                                                                             O



 danegaptidum
 danegaptide                                 (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid

 danégaptide                                 acide (2S,4R)-1-(2-aminoacétyl)-4-benzamidopyrrolidine-
                                             2-carboxylique

 danegaptida                                 ácido (2S,4R)-1-(2-aminoacetil)-4-benzamidopirrolidina-2-carboxílico

                                             C14H17N3O4

                                                         O        H CO H
                                                                      2
                                             H2N
                                                              N          O

                                                                     N
                                                                   H H




 daratumumabum #
 daratumumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens ADP-ribosyl cyclase
                                             1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)],
                                             Homo sapiens monoclonal antibody;
                                             gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-23*01
                                             (94.90%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -IGHG1*03 (123-452)],
                                             (225-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-
                                             KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -
                                             IGKC*01 (108'-214')]; (231-231'':234-234'')-bisdisulfide dimer

 daratumumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens ADP-ribosyl
                                             cyclase 1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1,
                                             T10)], Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-23*01
                                             (94.90%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -IGHG1*03 (123-452)],
                                             (225-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-
                                             107') -IGKC*01 (108'-214')]; dimère (231-231'':234-23''')-bisdisulfure

 daratumumab                                 inmunoglobulina G1-kappa, anti-[ADP-ribosil ciclasa 1 de Homo
                                             sapiens (CD38, hidrolasa 1 de ADP ciclico-ribosa, cADPr hidrolasa
                                             1, T10)], anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-23*01
                                             (94.90%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -IGHG1*03 (123-452)],
                                             (225-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-
                                             107') -IGKC*01 (108'-214')]; dímero (231-231'':234-23''')-bisdisulfuro




                                                                                                                  49
Recommended INN: List 63                                     WHO Drug Information, Vol. 24, No. 1, 2010


                           C6466H9996N1724O2010S42

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLLESGGG LVQPGGSLRL SCAVSGFTFN                  SFAMSWVRQA       PGKGLEWVSA        50
                           ISGSGGGTYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYFCAKDK       100
                           ILWFGEPVFD YWGQGTLVTV SSASTKGPSV                  FPLAPSSKST       SGGTAALGCL       150
                           VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT       200
                           QTYICNVNHK PSNTKVDKRV EPKSCDKTHT                  CPPCPAPELL       GGPSVFLFPP       250
                           KPKDTLMISR TPEVTCVVVD VSHEDPEVKF                  NWYVDGVEVH       NAKTKPREEQ       300
                           YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                  KALPAPIEKT       ISKAKGQPRE       350
                           PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS                  DIAVEWESNG       QPENNYKTTP       400
                           PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC                  SVMHEALHNH       YTQKSLSLSP       450
                           GK                                                                                  452

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                           ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPPTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 149-205              266-326  372-430
                                     22''-96'' 149''-205'' 266''-326'' 372''-430''
                           Intra-L 23'-88' 134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 225-214' 225''-214'''
                           Inter-H-H 231-231'' 234-234''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           302, 302''


 davalintidum #
 davalintide               amylin analogue
                           human islet amyloid polypeptide-(1-7)-peptidyl-
                           [11-L-arginine(K>R),18- L-arginine(K>R)]salmon
                           calcitonin-1 (Oncorhynchus keta)-(8-27)-peptidyl-human islet
                           amyloid polypeptide-(33-37)-peptidamide

 davalintide               analogue de l'amyline
                           polypeptide amyloïde d'îlots pancréatiques humains-(1-7)-peptidyl-
                           [11-L-arginine(K>R),18-L-arginine(K>R)]calcitonine-1 de saumon
                           (Oncorhynchus keta)-(8-27)-peptidyl-polypeptide amyloïde d'îlots
                           pancréatiques humains-(33-37)-peptidamide

 davalintida               análogo de la amilina
                           polipéptido amiloide de los islotes pancreáticos humanos-(1-7)-
                           peptidil-[11-L-arginina(K>R),18-L-arginina(K>R)]calcitonina-1 de
                           salmón (Oncorhynchus keta)-(8-27)-peptidil-polipéptido amiloide de
                           los islotes pancreáticos humanos -(33-37)-peptidamida

                           C152H248N50O49S2

                           H Lys      Cys     Asn     Thr     Ala    Thr    Cys     Val    Leu     Gly     Arg    Leu
                                                                                                    10
                               Ser     Gln    Glu     Leu     His    Arg     Leu     Gln    Thr     Tyr    Pro     Arg
                                                                                     20
                               Thr     Asn    Thr     Gly    Ser     Asn     Thr     Tyr NH2
                                                                      30




 elinogrelum
 elinogrel                 N-[(5-chlorothiophen-2-yl)sulfonyl]-N'-{4-[6-fluoro-7-(methylamino)-
                           2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]phenyl}urea

 élinogrel                 N-[(5-chlorothiophén-2-yl)sulfonyl]-N'-{4-[6-fluoro-7-(méthylamino)-
                           2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]phényl}urée




50
WHO Drug Information, Vol. 24, No. 1, 2010                                                                  Recommended INN: List 63


 elinogrel                                   N-[(5-clorotiofen-2-il)sulfonil]-N'-{4-[6-fluoro-7-(metilamino)-2,4-dioxo-
                                             1,4-dihidroquinazolin-3(2H)-il]fenil}urea

                                             C20H15ClFN5O5S2

                                                   H                        H
                                                   N                        N       O
                                             H3C
                                                                                N
                                                     F                                            O    O O
                                                                            O                           S
                                                                                            N         N
                                                                                            H         H
                                                                                                                S
                                                                                                                          Cl



 elisidepsinun
 elisidepsin                                 13,8-anhydro{N-[(4S)-4-methylhexanoyl]-D-valyl-L-threonyl-L-valyl-
                                             D-valyl-D-prolyl-L-ornithyl-D-alloisoleucyl-D-allothreonyl-
                                             D-alloisoleucyl-D-valyl-L-phenylalanyl-(2Z)-2-aminobut-2-enoyl-
                                             L-valine}

 élisidepsine                                13,8-anhydro{N-[(4S)-4-méthylhexanoyl]-D-valyl-L-thréonyl-L-valyl-
                                             D-valyl-D-prolyl-L-ornithyl-D-alloisoleucyl-D-allothréonyl-
                                             D-alloisoleucyl-D-valyl-L-phénylalanyl-(2Z)-2-aminobut-2-énoyl-
                                             L-valine}

 elisidepsina                                13,8-anhidro{N-[(4S)-4-metilhexanoil]-D-valil-L-treonil-L-valil-D-valil-
                                             D-prolil-L-ornitil-D-aloisoleucil-D-alotreonil-D-aloisoleucil-D-valil-
                                             L-fenilalanil-(2Z)-2-aminobut-2-enoil-L-valina}

                                             C75H124N14O16

                                                                        H2 N                                     CH3
                                                                                                      H3C         H        O
                                                                                            H3C
                                                                                                       O
                                                                                             H                        N                   CH3
                                                                 O      H                 O                           H
                                                                                    H       H               O                  HN       O
                                                                                    N
                                                                   N                        N
                                                                 H H                H     H H                                             H
                                                           N                    O
                                                                                          CH3   O           NH                 HN
                                             H3C       H            O                                                 H
                                                                                    CH3             H                 N
                                                                                                                                    O
                                                                                                H3C
                                             H3C               NH                   H3C            H             O    H             CH3
                                                   O                    O           H       CH3                       H3C
                                                                    H           H                     H3C
                                                                                N
                                                                    N                     NH
                                               H3C                  H H
                                                               CH3 HO             O
                                                                                CH3 O                           CH3
                                                                            H
                                                                                                    H CH3



 elpetriginum
 elpetrigine                                 3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine

 elpétrigine                                 3-(2,3,5-trichlorophényl)pyrazine-2,6-diamine

 elpetrigina                                 3-(2,3,5-triclorofenil)pirazina-2,6-diamina




                                                                                                                                                51
Recommended INN: List 63                                                WHO Drug Information, Vol. 24, No. 1, 2010




                                        C10H7Cl3N4

                                                                      NH2
                                                        N
                                        Cl                        N

                                                             NH2
                                                        Cl
                                                   Cl




 enisamii iodidum
 enisamium iodide                       4-(benzylcarbamoyl)-1-methylpyridin-1-ium iodide

 iodure d'énisamium                     iodure de 4-(benzylcarbamoyl)-1-méthylpyridinium

 ioduro de enisamio                     ioduro de 4-(bencilcarbamoil)-1-metilpiridin-1-io

                                        C14H15IN2O

                                                         O

                                                              N                I
                                                              H
                                               N
                                        H 3C




 eptacogum alfa pegolum (activatum) #
 eptacog alfa pegol (activated)         pegylated human coagulation factor VII, activated
                                        blood-coagulation factor VII (EC 3.4.21.21, serum prothrombin
                                        conversion accelerator), human factor VII light chain (135-262)-
                                        disulfide with human factor VII heavy chain, some sialyl units of the
                                        N-linked carbohydrates are mono-O-[a-methylpoly(oxyethylene)
                                        hydrogen phosphate] esterified (average value of the ratio factor
                                        VII/pegol is close to 1)

 eptacog alfa pégol (activé)            facteur VII humain de la coagulation pégylé, activé
                                        facteur VII de la coagulation sanguine (EC 3.4.21.21, accélérateur
                                        de conversion de la prothrombine sérique), (135-262) disulfure entre
                                        la chaîne légère et la chaîne lourde du facteur VII humain, quelques
                                        unités acide N-acétylneuraminique de la partie N-glycosyl sont
                                        estérifiées, mono-O-[a-méthylpoly(oxyéthylène)
                                        hydrogénophosphate] (rapport facteur VII/pegol voisin de 1)

 eptacog alfa pegol (activado)          factor VII de coagulación humano pegilado, activado
                                        factor VII de coagulación sanguínea (EC 3.4.21.21, acelerador de
                                        conversión de la protrombina de suero), (135-262) disulfuro entre la
                                        cadena ligera y la cadena pesada del factor VII humano, algunas
                                        unidades acido N-acetilneuraminico de la parte N-glicosilo están
                                        esterificadas, mono-O-[a-metilpoli(oxietileno) hidrogenofosfato]
                                        (relación factor VII/pegol cercano de 1)




52
WHO Drug Information, Vol. 24, No. 1, 2010                                                              Recommended INN: List 63




                                             C1982H3054N560O618S28

                                             Light chain / Chaîne légère / Cadena ligera
                                             ANAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50
                                             ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
                                             YCSDHTGTKR SCRCHEGYSL LADGVSCTPT VEYPCGKIPI LEKRNASKPQ 150
                                             GR                                                     152

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                               IVGGKVCP KGECPWQVLL LVNGAQLCGG                  TLINTIWVVS       AAHCFDKIKN       200
                                             WRNLIAVLGE HDLSEHDGDE QSRRVAQVII                  PSTYVPGTTN       HDIALLRLHQ       250
                                             PVVLTDHVVP LCLPERTFSE RTLAFVRFSL                  VSGWGQLLDR       GATALELMVL       300
                                             NVPRLMTQDC LQQSRKVGDS PNITEYMFCA                  GYSDGSKDSC       KGDSGGPHAT       350
                                             HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV                  SQYIEWLQKL       MRSEPRPGVL       400
                                             LRAPFP                                                                              406

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             17-22 50-61 55-70 72-81 91-102 98-112
                                             114-127 135-262 159-164 178-194 310-329 340-368

                                             Modified residues / Résidus modifiés / Residuos modificados
                                                          E                             CO2H H NH2
                                             6-7-14-16-19-20-25-26-29-35
                                                    4-carboxyGlu
                                                                               HO2C                   CO2H
                                             Glycosylation sites (S , N) / Sites de glycosylation (S , N) / Posiciones de glicosilación (S , N)
                                             Ser-52 Ser-60 Asn-145 Asn-322
                                              (β-Xyl)n-β-Glc→S-52              α-Fuc→S-60
                                                     n = 0-2
                                                 R→3-β-Gal→3-β-Gl-N→2-α-Man→6-
                                                                                        β-Man→4-β-Gl-N→4-β-Gl-N→N
                                                 R'→3-β-Gal→3-β-Gl-N→2-α-Man→3-
                                              R = α-Sia, R' = α-Sia or PEG-α-Sia or R' = α-Sia, R = α-Sia or PEG-α-Sia


                                              Fuc = 6-deoxy-L-galactopyranosyl
                                              Gal = D-galactopyranosyl
                                              Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl
                                              Man = D-mannopyranosyl
                                              PEG- = O-[α-methylpoly(oxyethylene) hydrogen phosphate]
                                              Sia = 5-N-acetyl-α-neuramin-2-yl
                                              Xyl = D-xylopyranosyl



 etamicastatum
 etamicastat                                 5-(2-aminoethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-
                                             1,3-dihydro-2H-imidazole-2-thione

 étamicastat                                 5-(2-aminoéthyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-
                                             1,3-dihydro-2H-imidazole-2-thione

 etamicastat                                 5-(2-aminoetil)-1-[(3R)-6,8-difluoro-3,4-dihidro-2H-cromen-3-il]-
                                             1,3-dihidro-2H-imidazol-2-tiona

                                             C14H15F2N3OS

                                                     F
                                                               O          S

                                                                              NH
                                                                          N
                                             F
                                                                      H


                                                               H2 N




                                                                                                                                               53
Recommended INN: List 63                               WHO Drug Information, Vol. 24, No. 1, 2010




 evatanepagum
 evatanepag                2-{3-[(N-{[4-(tert-butyl)phenyl]methyl}pyridine-
                           3-sulfonamido)methyl]phenoxy}acetic acid

 évatanépag                acide 2-{3-[(N-{[4-(tert-butyl)phényl]méthyl}pyridine-
                           3-sulfonamido)méthyl]phénoxy}acétique

 evatanepag                ácido 2-{3-[(N-{[4-(terc-butil)fenil]metil}piridina-
                           3-sulfonamido)metil]fenoxi}acético

                           C25H28N2O5S

                                         O     CO2H




                                     N
                                     S O                 CH3
                           N
                                      O
                                                 H3C   CH3




 fezakinumabum #
 fezakinumab               immunoglobulin G1-lambda, anti-[Homo sapiens interleukin 22 (IL22,
                           IL-22, ILTIF, IL-TIF)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-450) [Homo sapiens VH (IGHV1-2*02
                           (91.80%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*03 CH1
                           R120>K, CH3 K130>del (122-450)], (224-216')-disulfide with lambda
                           light chain (1'-217') [Homo sapiens V-LAMBDA (IGLV1-40*01
                           (96.00%) -IGLJ2*01 K123>Q) [9.3.11] (1'-111') -IGLC2*01 (112'-
                           217')]; (230-230'':233-233'')-bisdisulfide dimer

 fézakinumab               immunoglobuline G1-lambda, anti-[Homo sapiens interleukine 22
                           (IL22, IL-22, ILTIF, IL-TIF)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-450) [Homo sapiens VH (IGHV1-2*02
                           (91.80%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*03 CH1
                           R120>K, CH3 K130>del (122-450)], (224-216')-disulfure avec la
                           chaîne légère lamba (1'-217') [Homo sapiens V-LAMBDA (IGLV1-
                           40*01 (96.00%) -IGLJ2*01 K123>Q) [9.3.11] (1'-111') -IGLC2*01
                           (112'-217')]; dimère (230-230'':233-233'')-bisdisulfure

 fezakinumab               inmunoglobulina G1-lambda, anti-[interleukina 22 (IL22, IL-22, ILTIF,
                           IL-TIF) de Homo sapiens], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-450) [Homo sapiens VH (IGHV1-2*02
                           (91.80%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*03 CH1
                           R120>K, CH3 K130>del (122-450)], (224-216')-disulfuro con la
                           cadena ligera lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV1-
                           40*01 (96.00%) -IGLJ2*01 K123>Q) [9.3.11] (1'-111') -IGLC2*01
                           (112'-217')]; dímero (230-230'':233-233'')-bisdisulfuro




54
WHO Drug Information, Vol. 24, No. 1, 2010                                                             Recommended INN: List 63


                                             C6408H9886N1710O2016S44

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  NYYMHWVRQA       PGQGLEWVGW        50
                                             INPYTGSAFY AQKFRGRVTM TRDTSISTAY                  MELSRLRSDD       TAVYYCAREP       100
                                             EKFDSDDSDV WGRGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                                             KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                                             TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                                             PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                                             NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                                             QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                                             VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450

                                             Light chain / Chaîne légère / Cadena ligera
                                             QAVLTQPPSV SGAPGQRVTI SCTGSSSNIG                  AGYGVHWYQQ       LPGTAPKLLI 50
                                             YGDSNRPSGV PDRFSGSKSG TSASLAITGL                  QAEDEADYYC       QSYDNSLSGY 100
                                             VFGGGTQLTV LGQPKAAPSV TLFPPSSEEL                  QANKATLVCL       ISDFYPGAVT 150
                                             VAWKADSSPV KAGVETTTPS KQSNNKYAAS                  SYLSLTPEQW       KSHRSYSCQV 200
                                             THEGSTVEKT VAPTECS                                                            217

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        148-204       265-325  371-429
                                                       22''-96'' 148''-204'' 265''-325'' 371''-429''
                                             Intra-L 22'-90' 139'-198'
                                                      22'''-90''' 139'''-198'''
                                             Inter-H-L 224-216' 224''-216'''
                                             Inter-H-H 230-230'' 233-233''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             301, 301''


 filibuvirum
 filibuvir                                   (6R)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-
                                             3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-
                                             5,6-dihydro-2H-pyran-2-one

 filibuvir                                   (6R)-6-cyclopentyl-6-[2-(2,6-diéthylpyridin-4-yl)éthyl]-
                                             3-[(5,7-diméthyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)méthyl]-4-hydroxy-
                                             5,6-dihydro-2H-pyran-2-one

 filibuvir                                   (6R)-6-ciclopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-
                                             3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroxi-
                                             5,6-dihidro-2H-piran-2-ona

                                             C29H37N5O3

                                                                                            H3C
                                             H 3C
                                                                              O       O
                                                                                           N N               CH3
                                                     N                                                N
                                                                                              N

                                             H 3C                             OH

                     18
 flutemetamolum ( F)
               18                                   18
 flutemetamol ( F)                           2-{3-[ F]fluoro-4-(methylamino)phenyl}-1,3-benzothiazol-6-ol
               18                                   18
 flutémétamol ( F)                           2-[3-[ F]fluoro-4-(méthylamino)phényl]-1,3-benzothiazol-6-ol
               18                                   18
 flutemetamol ( F)                           2-{3-[ F]fluoro-4-(metilamino)fenil}-1,3-benzotiazol-6-ol
                                                         18
                                             C14H11[ F]N2OS

                                                                              18
                                                                                  F
                                             HO                S
                                                                                      NH
                                                               N                       CH3




                                                                                                                                               55
Recommended INN: List 63                             WHO Drug Information, Vol. 24, No. 1, 2010




 fonturacetamum
 fonturacetam              rac-2-[(4R)-2-oxo-4-phenylpyrolidin-1-yl]acetamide

 fonturacétam              rac-2-[(4R)-2-oxo-4-phénylpyrrolidin-1-yl)acétamide

 fonturacetam              rac-2-[(4R)-4-fenil-2-oxopirolidin-1-il]acetamid

                           C12H14N2O2


                                    H
                                                        and enantiomer
                                              O         et énantiomère
                                        N               y enantiómero
                                                  NH2
                                    O




 fresolimumabum #
 fresolimumab              immunoglobulin G4-kappa, anti-[Homo sapiens transforming growth
                           factor beta (TGFB or TGFbeta or TGF-beta, including TGF-beta-1 or
                           TGFB1, TGF-beta-2 or TGFB2 or G-TsF and TGF-beta-3 or
                           TGFB3)], Homo sapiens monoclonal antibody;
                           gamma4 heavy chain (1-447) [Homo sapiens VH (IGHV1-69*10
                           (89.70%) -(IGHD)-IGHJ3*01) [8.8.13] (1-120) -IGHG4*01 (121-447)],
                           (134-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                           V-KAPPA (IGKV3-20*01 (93.80%) -IGKJ5*01) [7.3.9] (1'-108') -
                           IGKC*01 (109'-215')]; (226-226'':229-229'')-bisdisulfide dimer

 frésolimumab              immunoglobuline G4-kappa, anti-[Homo sapiens facteur de
                           croissance transformant bêta (TGFB ou TGFbêta ou TGF-bêta,
                           comprenant TGF-bêta1 ou TGFB1, TGF-bêta2 ou TGFB2 ou G-TsF
                           et TGF-bêta3 ou TGFB3)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma4 (1-447) [Homo sapiens VH (IGHV1-69*10
                           (89.70%) -(IGHD)-IGHJ3*01) [8.8.13] (1-120) -IGHG4*01 (121-447)],
                           (134-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                           sapiens V-KAPPA (IGKV3-20*01 (93.80%) -IGKJ5*01) [7.3.9] (1'-
                           108') -IGKC*01 (109'-215')]; dimère (226-226'':229-229'')-bisdisulfure

 fresolimumab              inmunoglobulina G4-kappa, anti-[factor de crecimiento transformador
                           beta de Homo sapiens (TGFB o TGFbeta o TGF-beta, incluye TGF-
                           beta-1 o TGFB1, TGF-beta-2 o TGFB2 o G-TsF y TGF-beta-3 o
                           TGFB3)], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma4 (1-447) [Homo sapiens VH (IGHV1-69*10
                           (89.70%) -(IGHD)-IGHJ3*01) [8.8.13] (1-120) -IGHG4*01 (121-447)],
                           (134-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                           sapiens V-KAPPA (IGKV3-20*01 (93.80%) -IGKJ5*01) [7.3.9] (1'-
                           108') -IGKC*01 (109'-215')]; dímero (226-226'':229-229'')-bisdisulfuro




56
WHO Drug Information, Vol. 24, No. 1, 2010                                                             Recommended INN: List 63




                                             C6392H9926N1698O2026S44

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKKPGSSVKV SCKASGYTFS                  SNVISWVRQA       PGQGLEWMGG        50
                                             VIPIVDIANY AQRFKGRVTI TADESTSTTY                  MELSSLRSED       TAVYYCASTL       100
                                             GLVLDAMDYW GQGTLVTVSS ASTKGPSVFP                  LAPCSRSTSE       STAALGCLVK       150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTKT       200
                                             YTCNVDHKPS NTKVDKRVES KYGPPCPSCP                  APEFLGGPSV       FLFPPKPKDT       250
                                             LMISRTPEVT CVVVDVSQED PEVQFNWYVD                  GVEVHNAKTK       PREEQFNSTY       300
                                             RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS                  SIEKTISKAK       GQPREPQVYT       350
                                             LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                             DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE                  ALHNHYTQKS       LSLSLGK          447

                                             Light chain / Chaîne légère / Cadena ligera
                                             ETVLTQSPGT LSLSPGERAT LSCRASQSLG                  SSYLAWYQQK       PGQAPRLLIY 50
                                             GASSRAPGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYADSPITFG 100
                                             QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        147-203 261-321        367-425
                                                      22''-96'' 147''-203'' 261''-321'' 367''-425''
                                             Intra-L 23'-89' 135'-195'
                                                      23'''-89''' 135'''-195'''
                                             Inter-H-L 134-215' 134''-215'''
                                             Inter-H-H 226-226'' 229-229''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             297, 297''




 girentuximabum #
 girentuximab                                immunoglobulin G1-kappa, anti-[Homo sapiens carbonic anhydrase
                                             IX (CAIX, CA9, MN, G250)], chimeric monoclonal antibody;
                                             gamma1 heavy chain (1-449) [Mus musculus VH (IGHV5-6-2*01 -
                                             (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                                             449)], (222-214')-disulfide with kappa light chain (1'-214') [Mus
                                             musculus V-KAPPA (IGKV6-13*01 -IGKJ1*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'')-
                                             bisdisulfide dimer

 girentuximab                                immunoglobuline G1-kappa, anti-[Homo sapiens anhydrase
                                             carbonique IX (CAIX, CA9, MN, G250)], anticorps monoclonal
                                             chimérique;
                                             chaîne lourde gamma1 (1-449) [Mus musculus VH (IGHV5-6-2*01 -
                                             (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                                             449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214')
                                             [Mus musculus V-KAPPA (IGKV6-13*01 -IGKJ1*01) [6.3.9] (1'-107')
                                             -Homo sapiens IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-
                                             bisdisulfure

 girentuximab                                inmunoglobulina G1-kappa, anti-[anhidrasa carbónica IX de Homo
                                             sapiens (CAIX, CA9, MN, G250)], anticuerpo monoclonal quimérico;
                                             cadena pesada gamma1 (1-449) [Mus musculus VH (IGHV5-6-2*01
                                             -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                                             449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus
                                             musculus V-KAPPA (IGKV6-13*01 -IGKJ1*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-
                                             bisdisulfuro




                                                                                                                                               57
Recommended INN: List 63                                      WHO Drug Information, Vol. 24, No. 1, 2010


                           C6460H10006N1718O2018S48

                           Heavy chain / Chaîne lourde / Cadena pesada
                           DVKLVESGGG LVKLGGSLKL SCAASGFTFS                  NYYMSWVRQT       PEKRLELVAA        50
                           INSDGGITYY LDTVKGRFTI SRDNAKNTLY                  LQMSSLKSED       TALFYCARHR       100
                           SGYFSMDYWG QGTSVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSQRF MSTTVGDRVS ITCKASQNVV                  SAVAWYQQKP       GQSPKLLIYS 50
                           ASNRYTGVPD RFTGSGSGTD FTLTISNMQS                  EDLADFFCQQ       YSNYPWTFGG 100
                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202       263-323  369-427
                                     22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 222-214' 222''-214'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''



 gisadenafilum
 gisadenafil               5-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]pyridin-3-yl}-3-ethyl-
                           2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

 gisadénafil               5-{2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]pyridin-3-yl}-3-éthyl-
                           2-(2-méthoxyéthyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

 gisadenafilo              3-etil-5-{5-[(4-etilpiperazin-1-il)sulfonil]-2-etoxipiridin-3-il}-
                           2-(2-metoxietil)-2,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona

                           C23H33N7O5S

                                                                      O                          CH3
                                                                               N             O
                                               O O              HN
                                                                                   N
                                                  S
                                              N                       N
                                                                                       CH3
                           H3C        N
                                                          N       O       CH3



 givinostatum
 givinostat                {6-[(diethylamino)methyl]naphthalen-2-yl}methyl
                           [4-(hydroxycarbamoyl)phenyl]carbamate

 givinostat                [4-(hydroxycarbamoyl)phényl]carbamate de
                           {6-[(diéthylamino)méthyl]naphtalén-2-yl}méthyle

 givinostat                [4-(hidroxicarbamoil)fenil]carbamato de
                           {6-[(dietilamino)metil]naftalen-2-il}metilo




58
WHO Drug Information, Vol. 24, No. 1, 2010                                                              Recommended INN: List 63


                                             C24H27N3O4
                                                                                                              O
                                                                                                                      OH
                                                                                            O                     N
                                                                                                                  H
                                                H3C
                                                                                        O           N
                                                                                                    H
                                             H3C         N


 golnerminogenum pradenovecum #
 golnerminogene pradenovec                   a replication deficient human adenovirus 5 viral vector deleted in the
                                             E1, E4 and part of the E3 region and expressing a human tumour
                                             necrosis factor alpha (TNF-α) gene inserted in the E1 region and
                                             under the control of an Egr-1 promoter and the SV40
                                             polyadenylation sequence

 golnerminogène pradénovec                   vecteur viral adénovirus humain 5 sans capacité de réplication, dont
                                             les régions E1, E4 et une partie de la région E3 ont été supprimées,
                                             et exprimant un gène humain du facteur de nécrose tumorale alpha
                                             (TNF-α) inséré dans la région E1 et sous lecontrôle d'un promoteur
                                             Egr-1 et la séquence de polyadénylation SV40

 golnerminogén pradenovec                    vector viral adenovirus humano 5 sin capacidad de replicación con
                                             deleción de E1, E4 y parte de la región E3 y que expresa un gen
                                             humano del factor de necrosis tumoral alfa (TNF-α) insertado en la
                                             región E1 y bajo control de un promotor Egr-1 y la secuencia de
                                             poliadenilación de SV40


 gosogliptinum
 gosogliptin                                 (3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-
                                             1-yl]pyrrolidin-2-yl}methanone

 gosogliptine                                (3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)pipérazin-
                                             1-yl]pyrrolidin-2-yl}méthanone

 gosogliptina                                (3,3-difluoropirrolidin-1-il){(2S,4S)-4-[4-(pirimidin-2-il)piperazin-
                                             1-il]pirrolidin-2-il}metanona

                                             C17H24F2N6O

                                                                                O
                                                                         H
                                                                         N                  F
                                                                                    N           F
                                                                                H
                                                                N
                                                                     H
                                                N        N

                                                    N


 imagabalinum
 imagabalin                                  (3S,5R)-3-amino-5-methyloctanoic acid

 imagabaline                                 acide (3S,5R)-3-amino-5-méthyloctanoïque

 imagabalina                                 ácido (3S,5R)-3-amino-5-metiloctanoico

                                             C9H19NO2

                                                        H3 C   H H       NH2
                                                                               CO2H
                                             H 3C


                                                                                                                              59
Recommended INN: List 63                              WHO Drug Information, Vol. 24, No. 1, 2010


 imetelstatum
 imetelstat                3'-amino-3'-deoxy-P-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-P-
                           thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-P-thioguanylyl-(3'→5')-3'-
                           amino-2',3'-dideoxy-P-thioguanylyl-(3'→5')-3'-amino-2',3'-dideoxy-
                           P-thioguanylyl-(3'→5')-3'-amino-3'-deoxy-P-thiothymidylyl-(3'→5')-3'-
                           amino-3'-deoxy-P-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-
                           P-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-P-thioguanylyl-(3'→5')-
                           3'-amino-2',3'-dideoxy-P-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-
                           P-thiocytidylyl-(3'→5')-3'-amino-2',3'-dideoxy-P-thioadenylyl-(3'→5')-
                           3'-amino-2',3'-dideoxyadenosine 5'-{O-[2-hydroxy-
                           3-(hexadecanoylamino)propyl] hydrogen phosphorothioate}

 imételstat                5'-{O-[2-hydroxy-3-(hexadécanoylamino)propyl]
                           hydrogénophosphorothioate} de 3'-amino-3'-déoxy-P-thiothymidylyl-
                           (3'→5')-3'-amino-2',3'-didéoxy-P-thioadénylyl-(3'→5')-3'-amino-
                           2',3'-didéoxy-P-thioguanylyl-(3'→5')-3'-amino-2',3'-didéoxy-
                           P-thioguanylyl-(3'→5')-3'-amino-2',3'-didéoxy-P-thioguanylyl-(3'→5')-
                           3'-amino-3'-déoxy-P-thiothymidylyl-(3'→5')-3'-amino-3'-déoxy-
                           P-thiothymidylyl-(3'→5')-3'-amino-2',3'-didéoxy-P-thioadénylyl-
                           (3'→5')-3'-amino-2',3'-didéoxy-P-thioguanylyl-(3'→5')-3'-amino-
                           2',3'-didéoxy-P-thioadénylyl-(3'→5')-3'-amino-2',3'-didéoxy-
                           P-thiocytidylyl-(3'→5')-3'-amino-2',3'-didéoxy-P-thioadénylyl-(3'→5')-
                           3'-amino-2',3'-didéoxyadénosine

 imetelstat                5'-{O-[2-hidroxi-3-(hexadecanoilamino)propil] hidrógenofosforotioato}
                           de 3'-amino-3'-desoxi-P-tiotimidilil-(3'→5')-3'-amino-2',3'-didesoxi-
                           P-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxi-P-tioguanilil-(3'→5')-3'-
                           amino-2',3'-didesoxi-P-tioguanilil-(3'→5')-3'-amino-2',3'-didesoxi-
                           P-tioguanilil-(3'→5')-3'-amino-3'-desoxi-P-tiotimidilil-(3'→5')-3'-amino-
                           3'-desoxi-P-tiotimidilil-(3'→5')-3'-amino-2',3'-didesoxi-P-tioadenilil-
                           (3'→5')-3'-amino-2',3'-didesoxi-P-tioguanilil-(3'→5')-3'-amino-
                           2',3'-didesoxi-P-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxi-P-tiocitidilil-
                           (3'→5')-3'-amino-2',3'-didesoxi-P-tioadenilil-(3'→5')-3'-amino-
                           2',3'-didesoxiadenosina

                           C148H211N68O53P13S13
                           (3'-5')d(3'-amino-3'-deoxy-P-thio)( pT A G G G T T A G A C A A)
                                                                  H
                                                                  N
                                                       HO
                                                                    O                H3C
 insulinum degludecum
                               6.B29   2
 insulin degludec          N       -[N -(15-carboxypentadecanoyl)-L-γ-glutamyl]-des-B30-
                           L-threonine-insulin   human
                               6,B29   2
 insuline dégludec         N       -[N -(15-carboxypentadécanoyl)-L-γ-glutamyl]-dés-B30-
                           L-thréonine-insuline   humaine
                               6.B29   2
 insulina degludec         N       -[N -(15-carboxipentadecanoil)-L-γ-glutamil]-des-B30-
                           L-treonina-insulina   humana

                           C274H411N65O81S6
                            H Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu
                                                                        10
                                 Glu Asn Tyr Cys Asn OH
                                            20

                            H Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
                                                                        10
                              Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys OH
                                          20                                 N6
                                                                     H
                           HO2C                                      N
                                                                                  O
                                                                  O H CO2H



60
WHO Drug Information, Vol. 24, No. 1, 2010                                                             Recommended INN: List 63




 intetumumabum #
 intetumumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens integrin alpha-V
                                             (CD51, ITGAV, subunit of alphaV-beta3 or CD51/CD61 or vitronectin
                                             receptor or VNR, subunit of alphaV-beta5)], Homo sapiens
                                             monoclonal antibody;
                                             gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3-30*01
                                             (91.80%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*01 (120-449)],
                                             (222-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-
                                             KAPPA (IGKV3-11*01 (100.00%) -IGKJ3*01) [6.3.10] (1'-108') -
                                             IGKC*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer

 intétumumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens intégrine alpha-V
                                             (CD51, ITGAV, sous-unité de alphaV-bêta3 ou CD51/CD61 ou
                                             récepteur de la vitronectine ou VNR, sous-unité de alphaV-bêta5)],
                                             Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV3-30*01
                                             (91.80%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*01 (120-449)],
                                             (222-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ3*01) [6.3.10] (1'-
                                             108') -IGKC*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure

 intetumumab                                 inmunoglobulina G1-kappa, anti-[integrina alfa-V de Homo sapiens
                                             (CD51, ITGAV, subunidad de alfaV-beta3 o CD51/CD61 o receptor
                                             de la vitronectina o VNR, subunidad de alfaV-beta5)], anticuerpo
                                             monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV3-30*01
                                             (91.80%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*01 (120-449)],
                                             (222-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ3*01) [6.3.10] (1'-
                                             108')-IGKC*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro

                                             C6468H10008N1744O2006S40

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVESGGG VVQPGRSRRL SCAASGFTFS                  RYTMHWVRQA       PGKGLEWVAV        50
                                             ISFDGSNKYY VDSVKGRFTI SRDNSENTLY                  LQVNILRAED       TAVYYCAREA       100
                                             RGSYAFDIWG QGTMVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                             YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                             ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                             DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                             TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                             YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                             DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                             ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPPFTFG 100
                                             PGTKVDIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        146-202       263-323  369-427
                                                       22''-96'' 146''-202'' 263''-323'' 369''-427''
                                             Intra-L 23'-88' 135'-195'
                                                      23'''-88''' 135'''-195'''
                                             Inter-H-L 222-215' 222''-215'''
                                             Inter-H-H 228-228'' 231-231''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             299, 299''




                                                                                                                                               61
Recommended INN: List 63                                         WHO Drug Information, Vol. 24, No. 1, 2010



            124
 iodum ( I) girentuximabum #
         124I
 iodine ( ) girentuximab        immunoglobulin G1-kappa, anti-[Homo sapiens carbonic anhydrase
                                IX (CAIX, CA9, MN, G250)], chimeric monoclonal antibody
                                radiolabeled with iodine-124;
                                gamma1 heavy chain (1-449) [Mus musculus VH (IGHV5-6-2*01 -
                                (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                                449)], (222-214')-disulfide with kappa light chain (1'-214') [Mus
                                musculus V-KAPPA (IGKV6-13*01 -IGKJ1*01) [6.3.9] (1'-107') -
                                Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'')-
                                bisdisulfide dimer covalently linked to iodine-124
        124
 iodine (     I) girentuximab   immunoglobuline G1-kappa, anti-[Homo sapiens anhydrase
                                carbonique IX (CAIX, CA9, MN, G250)], anticorps monoclonal
                                chimérique marqué à l'iode 124;
                                chaîne lourde gamma1 (1-449) [Mus musculus VH (IGHV5-6-2*01 -
                                (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                                449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214')
                                [Mus musculus V-KAPPA (IGKV6-13*01 -IGKJ1*01) [6.3.9] (1'-107')
                                -Homo sapiens IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-
                                bisdisulfure lié de façon covalente à de l'iode 124
        124
 iodine (     I) girentuximab   inmunoglobulina G1-kappa, anti-[anhidrasa carbónica IX de Homo
                                sapiens (CAIX, CA9, MN, G250)], anticuerpo monoclonal quimérico
                                marcado con iodo 124;
                                cadena pesada gamma1 (1-449) [Mus musculus VH (IGHV5-6-2*01
                                -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                                449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus
                                musculus V-KAPPA (IGKV6-13*01 -IGKJ1*01) [6.3.9] (1'-107') -
                                Homo sapiens IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-
                                bisdisulfuro covalentemente ligado con iodo 124
                                                  124
                                C6460H(10006-n)     InN1718O2018S48

                                Heavy chain / Chaîne lourde / Cadena pesada
                                DVKLVESGGG LVKLGGSLKL SCAASGFTFS                  NYYMSWVRQT       PEKRLELVAA        50
                                INSDGGITYY LDTVKGRFTI SRDNAKNTLY                  LQMSSLKSED       TALFYCARHR       100
                                SGYFSMDYWG QGTSVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                Light chain / Chaîne légère / Cadena ligera
                                DIVMTQSQRF MSTTVGDRVS ITCKASQNVV                  SAVAWYQQKP       GQSPKLLIYS 50
                                ASNRYTGVPD RFTGSGSGTD FTLTISNMQS                  EDLADFFCQQ       YSNYPWTFGG 100
                                GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                LSSPVTKSFN RGEC                                                               214

                                Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                Intra-H 22-96        146-202       263-323  369-427
                                          22''-96'' 146''-202'' 263''-323'' 369''-427''
                                Intra-L 23'-88'      134'-194'
                                         23'''-88''' 134'''-194'''
                                Inter-H-L 222-214' 222''-214'''
                                Inter-H-H 228-228'' 231-231''

                                N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                299, 299''




62
WHO Drug Information, Vol. 24, No. 1, 2010                                                    Recommended INN: List 63


 isopropylis turofexoras
 turofexorate isopropyl                      propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-
                                             tetrahydroazepino[4,5-b]indole-5-carboxylate

 isopropyl de turofexorate                   3-(3,4-difluorobenzoyl)-1,1-diméthyl-1,2,3,6-tétrahydroazépino[4,5-
                                             b]indole-5-carboxylate de propan-2-yle

 turofexorato de isopropilo                  3-(3,4-difluorobenzoil)-1,1-dimetil-1,2,3,6-tetrahidroazepino[4,5-
                                             b]indol-5-carboxilato de propan-2-ilo

                                             C25H24F2N2O3

                                                                O             O       CH3

                                                                    N             O     CH3

                                             F                                NH

                                                    F       H3C
                                                                        CH3




 lagociclovirum
 lagociclovir                                2-amino-9-(2,3-dideoxy-3-fluoro-β-D-erythro-pentofuranosyl)-
                                             1,9-dihydro-6H-purin-6-on

 lagociclovir                                2-amino-9-(2,3-didéoxy-3-fluoro-β-D-érythro-pentofuranosyl)-
                                             1,9-dihydro-6H-purin-6-one

 lagociclovir                                2-amino-9-(2,3-didesoxi-3-fluoro-β-D-eritro-pentofuranosil)-
                                             1,9-dihidro-6H-purin-6-ona

                                             C10H12FN5O3

                                                        O

                                                                    N
                                                   HN

                                             H2N        N           N

                                              HO
                                                            O



                                                        F



 lebrikizumabum #
 lebrikizumab                                immunoglobulin G4-kappa, anti-[Homo sapiens interleukin 13 (IL13,
                                             IL-13)], humanized monoclonal antibody;
                                             gamma4 heavy chain [humanized VH (Homo sapiens IGHV2-70*01
                                             (82.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -Homo sapiens
                                             IGHG4*01 hinge S10>P (119-445)], (132-218')-disulfide with kappa
                                             light chain (1’-218’) [humanized V-KAPPA (Homo sapiens IGKV4-
                                             1*01 (79.20%) –IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens
                                             IGKC*01 (112'-218')]; (224-224":227-227")-bisdisulfide dimer




                                                                                                                    63
Recommended INN: List 63                                     WHO Drug Information, Vol. 24, No. 1, 2010


 lébrikizumab              immunoglobuline G4-kappa, anti-[Homo sapiens interleukine 13
                           (IL13, IL-13)], anticorps monoclonal humanisé;
                           chaîne lourde gamma4 [VH humanisé (Homo sapiens IGHV2-70*01
                           (82.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -Homo sapiens
                           IGHG4*01 charnière S10>P (119-445)], (132-218')-disulfure avec la
                           chaîne légère kappa (1’-218’) [V-KAPPA humanisé (Homo sapiens
                           IGKV4-1*01 (79.20%) –IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens
                           IGKC*01 (112'-218')]; dimère (224-224":227-227")-bisdisulfure

 lebrikizumab              inmunoglobulina G4-kappa, anti-[interleukina 13 de Homo sapiens
                           (IL13, IL-13)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma4 [VH humanizada (Homo sapiens IGHV2-
                           70*01 (82.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -Homo sapiens
                           IGHG4*01 bisagra S10>P (119-445)], (132-218')-disulfuro con la
                           cadena ligera kappa (1’-218’) [V-KAPPA humanizada (Homo
                           sapiens IGKV4-1*01 (79.20%) –IGKJ4*01) [10.3.9] (1'-111') -Homo
                           sapiens IGKC*01 (112'-218')]; dímero (224-224":227-227")-
                           bisdisulfuro

                           C6434H9972N1700O2034S50

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVTLRESGPA LVKPTQTLTL TCTVSGFSLS                  AYSVNWIRQP       PGKALEWLAM        50
                           IWGDGKIVYN SALKSRLTIS KDTSKNQVVL                  TMTNMDPVDT       ATYYCAGDGY       100
                           YPYAMDNWGQ GSLVTVSSAS TKGPSVFPLA                  PCSRSTSEST       AALGCLVKDY       150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTKTYT       200
                           CNVDHKPSNT KVDKRVESKY GPPCPPCPAP                  EFLGGPSVFL       FPPKPKDTLM       250
                           ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV                  EVHNAKTKPR       EEQFNSTYRV       300
                           VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI                  EKTISKAKGQ       PREPQVYTLP       350
                           PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE                  SNGQPENNYK       TTPPVLDSDG       400
                           SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL                  HNHYTQKSLS       LSLGK            445

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSPDS LSVSLGERAT INCRASKSVD                  SYGNSFMHWY       QQKPGQPPKL 50
                           LIYLASNLES GVPDRFSGSG SGTDFTLTIS                  SLQAEDVAVY       YCQQNNEDPR 100
                           TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                           QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                           THQGLSSPVT KSFNRGEC                                                           218

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-95 145-201              259-319 365-423
                                    22''-95'' 145''-201'' 259''-319'' 365''-423''
                           Intra-L 23'-92' 138'-198'
                                    23'''-92''' 138'''-198'''
                           Inter-H-L 132-218' 132''-218'''
                           Inter-H-H 224-224'' 227-227''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           295, 295''


 lersivirinum
 lersivirine               5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzene-
                           1,3-dicarbonitrile

 lersivirine               5-{[3,5-diéthyl-1-(2-hydroxyéthyl)-1H-pyrazol-4-yl]oxy}benzène-
                           1,3-dicarbonitrile

 lersivirina               5-{[3,5-dietil-1-(2-hidroxietil)-1H-pirazol-4-il]oxi}benceno-
                           1,3-dicarbonitrilo

                           C17H18N4O2

                                                H3C         CN
                           HO               N
                                        N
                                                    O               CN
                                  H3C




64
WHO Drug Information, Vol. 24, No. 1, 2010                                                     Recommended INN: List 63


 levomequitazinum
 levomequitazine                             10-{[(3S)-1-azabicyclo[2.2.2]octan-3-yl]methyl}-10H-phenothiazine

 lévoméquitazine                             10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylméthyl]-10H-phénothiazine

 levomequitazina                             10-{[(3S)-1-azabiciclo[2.2.2]octan-3-il]metil}-10H-fenotiazina

                                             C20H22N2S




                                                         N
                                                             H
                                                S                        N



 litronesibum
 litronesib                                  (-)-N-{4-(2,2-dimethylpropanoyl)-
                                             5-{[2-(ethylamino)ethanesulfonamido]methyl}-5-phenyl-4,5-dihydro-
                                             1,3,4-thiadiazol-2-yl}-2,2-dimethylpropanamide

 litronésib                                  (-)-N-{4-(2,2-diméthylpropanoyl)-
                                             5-{[2-(éthylamino)éthanesulfonamido]méthyl}-5-phényl-4,5-dihydro-
                                             1,3,4-thiadiazol-2-yl}-2,2-diméthylpropanamide

 litronesib                                  (-)-N-{4-(2,2-dimetilpropanoil)-
                                             5-{[2-(etilamino)etanosulfonamido]metil}-5-fenil-4,5-dihidro-
                                             1,3,4-tiadiazol-2-il}-2,2-dimetilpropanamida

                                             C23H37N5O4S2

                                                                             CH3
                                                                     H3C
                                               H3C   CH3                      CH3
                                                             H                                        or enantiomer
                                                             N       N                                   (-)-isomer
                                             H3 C                        N    O
                                                                             H             H         ou énantiomère
                                                         O       S           N             N   CH3      (-)-isomère
                                                                                  S                   o enantiómero
                                                                                 O O                    (-)-isómero



 lomitapidum
 lomitapide                                  N-(2,2,2-trifluoroethyl)-9-(4-{4-[4'-(trifluoromethyl)[1,1'-biphenyl]-
                                             2-carboxamido]piperidin-1-yl}butyl)-9H-fluorene-9-carboxamide

 lomitapide                                  N-(2,2,2-trifluoroéthyl)-9-(4-{4-[4'-(trifluorométhyl)[1,1'-biphényl]-
                                             2-carboxamido]pipéridin-1-yl}butyl)-9H-fluorène-9-carboxamide

 lomitapida                                  N-(2,2,2-trifluoroetil)-9-(4-{4-[4'-(trifluorometil)[1,1'-bifenil]-
                                             2-carboxamido]piperidin-1-il}butil)-9H-fluoreno-9-carboxamida

                                             C39H37F6N3O2

                                                             H
                                                     O       N       CF3


                                                                             N             O

                                                                                       N
                                                                                       H



                                                                             F3C


                                                                                                                      65
Recommended INN: List 63                               WHO Drug Information, Vol. 24, No. 1, 2010




 losmapimodum
 losmapimod                6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-
                           N-(2,2-dimethylpropyl)pyridine-3-carboxamide

 losmapimod                6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-méthylphényl]-
                           N-(2,2-diméthylpropyl)pyridine-3-carboxamide

 losmapimod                6-[5-(ciclopropilcarbamoil)-3-fluoro-2-metilfenil]-
                           N-(2,2-dimetilpropil)piridina-3-carboxamida

                           C22H26FN3O2

                                                           O
                                                                          CH3
                                     O           N             N
                                                               H
                                                                   H3C   CH3
                                 N
                                 H
                                                 CH3
                                           F



 miravirsenum
 miravirsen                all-P-ambo-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-2'-
                           deoxy-P-thiocytidylyl-(3'→5')-2'-O,4'-C-methylene-P-thioadenylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O,4'-C-
                           methylene-P-thioguanylyl-(3'→5')-5-methyl-2'-O,4'-C-methylene-
                           P-thiouridylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-
                           P-thioadenylyl-(3'→5')-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-
                           (3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-5-methyl-2'-O,4'-C-
                           methylene-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-5-methyl-
                           2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-5-methyl-2'-O,4'-C-
                           methylene-P-thiocytidine

 miravirsen                all-P-ambo-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-
                           déoxy-P-thiocytidylyl-(3'→5')-2'-O,4'-C-méthylène-P-thioadénylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O,4'-C-
                           méthylène-P-thioguanylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-
                           P-thiouridylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-
                           P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-
                           (3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-
                           méthylène-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-5-méthyl-
                           2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-5-méthyl-2'-O,4'-C-
                           méthylènecytidine

 miravirsén                todo-P-ambo-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-
                           desoxi-P-tiocitidilil-(3'→5')-2'-O,4'-C-metileno-P-tioadenilil-(3'→5')-P-
                           tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-O,4'-C-metileno-
                           P-tioguanilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-2'-
                           desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-5-metil-2'-
                           O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-5-
                           metil-2'-O,4'-C-metileno-P-tioctidilil-(3'→5')-P-tiotimidilil-(3'→5')-5-
                           metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-5-metil-2'-O,4'-C-
                           metileno-P-tiocitidina




66
WHO Drug Information, Vol. 24, No. 1, 2010                                                                     Recommended INN: List 63


                                             C156H195N49O83P14S14

                                             (3'-5')(P-thio)(mC-dC-A-dT-dT-G-T-dC-dA-mC-dA-mC-dT-mC-mC)
                                              A                 N          G        H2N
                                                                  N           NH2                                       NH
                                               OH                                                               N             O
                                                      O           N       N                  OH
                                                                                                       O           N    N
                                             H2C
                                                                  H                         H2C
                                                HO        O
                                                                                                               H
                                                                                              HO           O
                                                      T               H
                                                              O       N       O                   mC O              N       NH2
                                               OH                                           OH
                                                      O           N                                O           N
                                                                              CH3                                           CH3
                                             H2C                                        H2C
                                                                  H                                        H
                                                HO        O                                 HO         O



 mocetinostatum
 mocetinostat                                N-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-
                                             2-yl]amino}methyl)benzamide

 mocétinostat                                N-(2-aminophényl)-4-({[4-(pyridin-3-yl)pyrimidin-
                                             2-yl]amino}méthyl)benzamide

 mocetinostat                                N-(2-aminofenil)-4-({[4-(piridin-3-il)pirimidin-
                                             2-il]amino}metil)benzamida

                                             C23H20N6O

                                                              O

                                                          N
                                                          H                         H
                                                NH2                                 N       N                      N

                                                                                        N




 modithromycinum
 modithromycin                               N-[(1R,2R,3R,6R,8R,9R,10R,13E,16S,17E,18R)-3-ethyl-2-hydroxy-
                                             2,6,8,10,16,18-hexamethyl-5,7-dioxo-13-{[6-(1H-pyrazol-1-yl)pyridin-
                                             3-yl]methoxyimino}-9-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
                                             hexopyranosyl]oxy}-4,11,15-trioxabicyclo[8.5.4]nonadecane-
                                             17-ylidene]acetamide

 modithromycine                              N-[(1R,2R,3R,6R,8R,9R,10R,13E,16S,17E,18R)-3-éthyl-2-hydroxy-
                                             2,6,8,10,16,18-tétraméthyl-5,7-dioxo-13-({[6-(1H-pyrazol-1-yl)pyridin-
                                             3-yl]méthoxy}imino)-9-{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-xylo-
                                             hexopyranosyl]oxy}-4,11,15-trioxabicyclo[8.5.4]nonadéc-
                                             17-ylidène]acétamide

 moditromicina                               N-[(1R,2R,3R,6R,8R,9R,10R,13E,16S,17E,18R)-3-etil-2-hidroxi-
                                             2,6,8,10,16,18-hexametil-5,7-dioxo-13-{[6-(1H-pirazol-1-il)piridin-
                                             3-il]metoxiimino}-9-{[3,4,6-tridesoxi-3-(dimetilamino)-β-D-xilo-
                                             hexopiranosil]oxi}-4,11,15-trioxabiciclo[8.5.4]nonadecane-
                                             17-ilidene]acetamido




                                                                                                                                     67
Recommended INN: List 63                                       WHO Drug Information, Vol. 24, No. 1, 2010


                           C43H64N6O11

                                                                      O

                                                              H3C         N
                                    N                 O             H             CH3
                                                              H3C
                                                      N                            H
                                N                                                   OH
                                N       H3C               O            O              CH3
                                                                      CH3 H
                                                  O
                                                                       H              H
                                                           O              O
                                                                H      CH3                CH3

                                    H3C   N           OH       O                  O
                                              CH3                       H CH3



 naluzotanum
 naluzotan                 N-(3-{4-[4-(1-cyclohexylmethanesulfonamido)butyl]piperazin-
                           1-yl}phenyl)acetamide

 naluzotan                 N-(3-{4-[4-(1-cyclohexylméthanesulfonamido)butyl]pipérazin-
                           1-yl}phényl)acétamide

 naluzotán                 N-(3-{4-[4-(1-ciclohexilmetanosulfonamido)butil]piperazin-
                           1-il}fenil)acetamida

                           C23H38N4O3S

                                                                                                O

                                        O O                                   N             N       CH3
                                                                                            H
                                          S                           N
                                              N
                                              H



 nelotanserinum
 nelotanserin              1-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-
                           3-(2,4-difluorophenyl)urea

 nélotansérine             1-[3-(4-bromo-1-méthyl-1H-pyrazol-5-yl)-4-méthoxyphényl]-
                           3-(2,4-difluorophényl)urée

 nelotanserina             1-[3-(4-bromo-1-metil-1H-pirazol-5-il)-4-metoxifenil]-
                           3-(2,4-difluorofenil)urea

                           C18H15BrF2N4O2

                                                               H 3C
                                                                      N N
                                          H       H
                                          N       N

                                              O                          Br
                           F              F                           OCH3




68
WHO Drug Information, Vol. 24, No. 1, 2010                                                             Recommended INN: List 63


 ocriplasminum #
 ocriplasmin                                 truncated human plasmin:
                                             human plasmin heavy chain A-(543-561)-peptide (548-666;558-566)-
                                             bisdisulfide with human plasmin light chain B

 ocriplasmine                                plasmine humaine tronquée :
                                             chaîne lourde A de la plasmine humaine-(543-561)-peptide (548-
                                             666;558-566)-bisdisulfure avec la chaîne légère B de la plasmine
                                             humaine

 ocriplasmina                                plasmina humana truncada:
                                             cadena pesada A de la plasmina humana-(543-561)-péptido (548-
                                             666;558-566)-bisdisulfuro con la cadena ligera B de la plasmina
                                             humana

                                             C1214H1890N338O348S14

                                             Truncated heavy chain / Chaîne lourde tronquée/ Cadena pesada truncada
                                                                                                              APSFDCGK 550
                                             PQVEPKKCPG R                                                              561

                                             Light chain / Chaîne légère / Cadena ligera
                                                               VVGGCVAHP HSWPWQVSLR            TRFGMHFCGG       TLISPEWVLT       600
                                             AAHCLEKSPR PSSYKVILGA HQEVNLEPHV                  QEIEVSRLFL       EPTRKDIALL       650
                                             KLSSPAVITD KVIPACLPSP NYVVADRTEC                  FITGWGETQG       TFGAGLLKEA       700
                                             QLPVIENKVC NRYEFLNGRV QSTELCAGHL                  AGGTDSCQGD       SGGPLVCFEK       750
                                             DKYILQGVTS WGLGCARPNK PGVYVRVSRF                  VTWIEGVMRN       N                791

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             548-666 558-566 588-604 680-747 710-726 737-765


 olodaterolum
 olodaterol                                  6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-
                                             1,1-diméthyléthyl]amino}ethyl]-2H-1,4-benzoxazin-3(4H)-one

 olodatérol                                  6-hydroxy-8-[(1R)-1-hydroxy-2-{[2-(4-méthoxyphényl)-
                                             1,1-diméthyléthyl]amino}éthyl]-2H-1,4-benzoxazin-3(4H)-one

 olodaterol                                  6-hidroxi-8-[(1R)-1-hidroxi-2-{[1-(4-metoxifenil)-2-metilpropan-
                                             2-il]amino}etil]-2H-1,4-benzoxazin-3(4H)-ona

                                             C21H26N2O5

                                                             H OH
                                                                       H
                                             HO                        N

                                                                      H3C     CH3
                                                               O                                OCH3
                                                     HN

                                                           O

 razupenemum
 razupenem                                   (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3-({4-[(5S)-5-methyl-
                                             2,5-dihydro-1H-pyrrol-3-yl]-1,3-thiazol-2-yl}sulfanyl)-7-oxo-
                                             1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

 razupénem                                   acide (4R,5S,6S)-6-[(1R)-1-hydroxyéthyl]-4-méthyl-3-({4-[(5S)-
                                             5-méthyl-2,5-dihydro-1H-pyrrol-3-yl]thiazol-2-yl}sulfanyl)-7-oxo-
                                             1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique

 razupenem                                   ácido (4R,5S,6S)-6-[(1R)-1-hidroxietil]-4-metil-3-({4-[(5S)-5-metil-
                                             2,5-dihidro-1H-pirrol-3-il]-1,3-tiazol-2-il}sulfanil)-7-oxo-
                                             1-azabiciclo[3.2.0]hept-2-eno-2-carboxílico



                                                                                                                                               69
Recommended INN: List 63                                      WHO Drug Information, Vol. 24, No. 1, 2010


                           C18H21N3O4S2

                                                    CO2H
                                    O
                            H3C               N
                                                         S
                           HO                         H        N
                                  H       H   H     CH3 S                  H
                                                                           CH3
                                                                      NH



 ridaforolimusum
 ridaforolimus             (1R,2R,4S)-4-[(2R)-2-
                           {(3S,6R,7E,9R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                           9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-
                           1,5,11,28,29-pentaoxo-
                           1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34
                           a-tetracosahydro-3H-23,27-epoxypyrido[2,1-
                           c][1,4]oxaazacyclohentricosin-3-yl}propyl]-2-methoxycyclohexyl
                           dimethylphosphinate

 ridaforolimus             (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)
                           -12-[(1R)-2-{(1S,3R,4R)-4-[(diméthylphosphinoyl)oxy]-
                           3-méthoxycyclohexyl}-1-méthyléthyl]-1,18-dihydroxy-
                           19,30-diméthoxy-15,17,21,23,29,35-hexaméthyl-11,36-dioxa-
                                                 4,9
                           4-azatricyclo[30.3.1.0 ]hexatriaconta-16,24,26,28-tétraène-
                           2,3,10,14,20-pentone

 ridaforolimus             (1R,2R,4S)-4-[(2R)-2-
                           {(3S,6R,7E,9R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                           9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-
                           1,5,11,28,29-pentaoxo-
                           1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34
                           a-tetracosahidro-3H-23,27-epoxipirido[2,1-
                           c][1,4]oxaazaciclohentricosin-3-il}propil]-2-metoxiciclohexil
                           dimetilfosfinato

                           C53H84NO14P

                                        H3C CH3
                                           P
                                         O   O
                                    H
                                H
                           H3CO
                                                    H
                                                        CH3
                                          O             H O        H OH
                                      H         H                                O
                                                O
                                                                   H
                                      N         O         H3C H CH3 OCH3
                                                               CH3
                                                OH      H            H3C H
                                                  O                                   H
                                      O
                                                                                     CH3
                                          H                  H OCH3
                                          H3C




70
WHO Drug Information, Vol. 24, No. 1, 2010                                                             Recommended INN: List 63




 rilotumumabum #
 rilotumumab                                 immunoglobulin G2-kappa, anti-[Homo sapiens hepatocyte growth
                                             factor (HGF, scatter factor, SF, hepatopoeitin A)], Homo sapiens
                                             monoclonal antibody;
                                             gamma2 heavy chain (1-446) [Homo sapiens VH (IGHV4-59*01
                                             (96.90%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) -IGHG2*01 (121-446)],
                                             (134-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                                             V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ5*01) [6.3.10] (1'-108') -
                                             IGKC*01 (109'-215')]; (222-222'':223-223'':226-226'':229-229'')-
                                             tetradisulfide dimer

 rilotumumab                                 immunoglobuline G2-kappa, anti-[Homo sapiens facteur de croissance
                                             de l'hépatocyte (HGF, facteur dispersant, SF, hépatopoïétine A)],
                                             Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma2 (1-446) [Homo sapiens VH (IGHV4-59*01
                                             (96.90%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) -IGHG2*01 (121-446)],
                                             (134-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ5*01) [6.3.10] (1'-
                                             108') -IGKC*01 (109'-215')]; dimère (222-222'':223-223'':226-226'':229-
                                             229'')-tétradisulfure

 rilotumumab                                 inmunoglobulina G2-kappa, anti-[factor de crecimiento de hepatocitos
                                             de Homo sapiens (HGF, factor dispersante, SF, hepatopoyetina A)],
                                             anticuerpo monoclonal de Homo sapiens ;
                                             cadena pesada gamma2 (1-446) [Homo sapiens VH (IGHV4-59*01
                                             (96.90%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) -IGHG2*01 (121-446)],
                                             (134-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ5*01) [6.3.10] (1'-
                                             108') -IGKC*01 (109'-215')]; dímero (222-222'':223-223'':226-226'':229-
                                             229'')-tetradisulfuro

                                             C6464H9932N1708O2010S46

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQESGPG LVKPSETLSL TCTVSGGSIS                  IYYWSWIRQP       PGKGLEWIGY        50
                                             VYYSGSTNYN PSLKSRVTIS VDTSKNQFSL                  KLNSVTAADT       AVYYCARGGY       100
                                             DFWSGYFDYW GQGTLVTVSS ASTKGPSVFP                  LAPCSRSTSE       STAALGCLVK       150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSNFGTQT       200
                                             YTCNVDHKPS NTKVDKTVER KCCVECPPCP                  APPVAGPSVF       LFPPKPKDTL       250
                                             MISRTPEVTC VVVDVSHEDP EVQFNWYVDG                  VEVHNAKTKP       REEQFNSTFR       300
                                             VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP                  IEKTISKTKG       QPREPQVYTL       350
                                             PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPMLDSD       400
                                             GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVMTQSPAT LSVSPGERAT LSCRASQSVD                  SNLAWYRQKP       GQAPRLLIYG 50
                                             ASTRATGIPA RFSGSGSGTE FTLTISSLQS                  EDFAVYYCQQ       YINWPPITFG 100
                                             QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-95        147-203       260-320  366-424
                                                      22''-95'' 147''-203'' 260''-320'' 366''-424''
                                             Intra-L 23'-88' 135'-195'
                                                      23'''-88''' 135'''-195'''
                                             Inter-H-L 134-215' 134''-215'''
                                             Inter-H-H 222-222'' 223-223'' 226-226'' 229-229''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             296, 296''




                                                                                                                                               71
Recommended INN: List 63                                     WHO Drug Information, Vol. 24, No. 1, 2010


 rontalizumabum #
 rontalizumab              immunoglobulin G1-kappa, anti-[Homo sapiens interferon alpha
                           (IFN-alpha)], humanized monoclonal antibody;
                           gamma1 heavy chain [humanized VH (Homo sapiens IGHV3-74*01
                           (76.30%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens
                           IGHG1*03, CH1 R120>K (118-447)], (220-218')-disulfide with kappa
                           light chain (1'-218') [humanized V-KAPPA (Homo sapiens IGKV1-
                           39*01 (83.80%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens
                           IGKC*01 (112'-218')]; (226-226":229-229")-bisdisulfide dimer

 rontalizumab              immunoglobuline G1-kappa, anti-[Homo sapiens interféron alpha
                           (IFN-alpha)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 [VH humanisé (Homo sapiens IGHV3-74*01
                           (76.30%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens
                           IGHG1*03, CH1 R120>K (118-447)], (220-218')-disulfure avec la
                           chaîne légère kappa (1'-218') [V-KAPPA humanisé (Homo sapiens
                           IGKV1-39*01 (83.80%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens
                           IGKC*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure

 rontalizumab              inmunoglobulina G1-kappa, anti-[interferón alfa de Homo sapiens
                           (IFN-alpha)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 [VH humanizada (Homo sapiens IGHV3-
                           74*01 (76.30%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens
                           IGHG1*03, CH1 R120>K (118-447)], (220-218')-disulfuro con la
                           cadena ligera kappa (1'-218') [V-KAPPA humanizada (Homo sapiens
                           IGKV1-39*01 (83.80%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens
                           IGKC*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro

                           C6486H9990N1722O2026S44

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCATSGYTFT                  EYIIHWVRQA       PGKGLEWVAS        50
                           INPDYDITNY NQRFKGRFTI SLDKSKRTAY                  LQMNSLRAED       TAVYYCASWI       100
                           SDFFDYWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                           NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                           LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQSVS                  TSSYSYMHWY       QQKPGKAPKV 50
                           LISYASNLES GVPSRFSGSG SGTDFTLTIS                  SLQPEDFATY       YCQHSWGIPR 100
                           TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                           QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                           THQGLSSPVT KSFNRGEC                                                           218

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 144-200              261-321  367-425
                                    22''-96'' 144''-200'' 261''-321'' 367''-425''
                           Intra-L 23'-92' 138'-198'
                                    23'''-92''' 138'''-198'''
                           Inter-H-L 220-218' 220''-218'''
                           Inter-H-H 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           297, 297''


 semaglutidum
                            6.26
 semaglutide               N -{18-[N-(17-carboxyheptadecanoyl)-L-γ-glutamyl]-10-oxo-
                           3,6,12,15-tetraoxa-9,18-diazaoctadecanoyl}-[8-(2-amino-2-propanoic
                           acid),34-L-arginine]human glucagon-like peptide 1(7-37)
                            6.26
 sémaglutide               N -{18-[N-(17-carboxyheptadécanoyl)-L-γ-glutamyl]-10-oxo-
                           3,6,12,15-tétraoxa-9,18-diazaoctadécanoyl}-[8-(acide 2-amino-
                           2-méthylpropanoïque),34-L-arginine]peptide 1(7-37) apparenté au
                           glucagon humain (GLP-1(7-37))



72
WHO Drug Information, Vol. 24, No. 1, 2010                                                                         Recommended INN: List 63


                                              6.26
 semaglutida                                 N -{18-[N-(17-carboxiheptadecanoil)-L-γ-glutamil]-10-oxo-
                                             3,6,12,15-tetraoxa-9,18-diazaoctadecanoil}-[8-(ácido 2-amino-
                                             2-metilpropanoico ),34-L-arginina]péptido 1(7-37) similar al glucagón
                                             tipo 1 humano

                                             C187H291N45O59

                                                        H3C        CH3

                                             H His      N                Glu     Gly      Thr       Phe        Thr    Ser       Asp        Val   Ser
                                                   7    H                          10
                                                                   O
                                                 HO2C
                                                                                                                                           Glu   OH
                                                                                                    O
                                                                                                                                     O
                                                                                                               O                            NH
                                                                                              HN                            O
                                                                                                           O                           O
                                                                                                                      O
                                                                                                                                N6
                                                  Ser        Tyr       Leu      Glu      Gly        Gln        Ala   Ala         Lys       Glu   Phe
                                                                       20

                                                  Ile   Ala        Trp       Leu        Val        Arg     Gly       Arg    Gly          OH
                                                            30                                                                  37




 serdemetanum
 serdemetan                                  N-[2-(1H-indol-3-yl)ethyl]-N'-(pyridin-4-yl)benzene-1,4-diamine

 serdémétan                                  N-[2-(1H-indol-3-yl)éthyl]-N'-(pyridin-4-yl)benzène-1,4-diamine

 serdemetán                                  N-[2-(1H-indol-3-il)etil]-N'-(piridin-4-il)benceno-1,4-diamina

                                             C21H20N4

                                                        H                                      H
                                                        N                                      N

                                                                                                               N
                                                                            N
                                                                            H



 setileutonum
 setileuton                                  4-(4-fluorophenyl)-7-[({5-[(2S)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-
                                             1,3,4-oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one

 sétileuton                                  4-(4-fluorophényl)-7-[({5-[(2S)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-
                                             1,3,4-oxadiazol-2-yl}amino)méthyl]-2H-chromèn-2-one

 setileutón                                  4-(4-fluorofenil)-7-[({5-[(2S)-1,1,1-trifluoro-2-hidroxibutan-2-il]-
                                             1,3,4-oxadiazol-2-il}amino)metil]-2H-cromen-2-ona

                                             C22H17F4N3O4

                                                                                               N       N
                                             F
                                                                                        N          O                 CH3
                                                                                        H
                                                                                                       HO CF3

                                                                         O

                                                                    O




                                                                                                                                                       73
Recommended INN: List 63                                     WHO Drug Information, Vol. 24, No. 1, 2010


 sifalimumabum #
 sifalimumab               immunoglobulin G1-kappa, anti-[Homo sapiens interferon alpha
                           (IFN-alpha)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV1-18*01
                           (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1
                           R120>K (117-446)], (219-213')-disulfide with kappa light chain (1'-
                           213') [Homo sapiens V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ1*01)
                           [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (225-225'':228-228'')-
                           bisdisulfide dimer

 sifalimumab               immunoglobuline G1-kappa, anti-[Homo sapiens interféron alpha
                           (IFN-alpha)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV1-18*01
                           (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1
                           R120>K (117-446)], (219-215')-disulfure avec la chaîne légère kappa
                           (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01 (99.00%) -
                           IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (225-
                           225'':228-228'')-bisdisulfure

 sifalimumab               inmunoglobulina G1-kappa, anti-[interferón alfa (IFN-alfa) de Homo
                           sapiens], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV1-18*01
                           (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1
                           R120>K (117-446)], (219-215')-disulfuro con la cadena ligera kappa
                           (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01 (99.00%) -
                           IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (225-
                           225'':228-228'')-bisdisulfuro

                           C6396H9922N1714O2008S42

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  SYSISWVRQA       PGQGLEWMGW        50
                           ISVYNGNTNY AQKFQGRVTM TTDTSTSTAY                  LELRSLRSDD       TAVYYCARDP       100
                           IAAGYWGQGT LVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                           EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                           VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA                  PELLGGPSVF       LFPPKPKDTL       250
                           MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                           VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                           PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                           GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPGT LSLSPGERAT LSCRASQSVS                  STYLAWYQQK       PGQAPRLLIY 50
                           GASSRATGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYGSSPRTFG 100
                           QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                           GLSSPVTKSF NRGEC                                                              215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 143-199 260-320              366-424
                                    22''-96'' 143''-199'' 260''-320'' 366''-424''
                           Intra-L 23'-89' 135'-195'
                                    23'''-89''' 135'''-195'''
                           Inter-H-L 219-215' 219''-215'''
                           Inter-H-H 225-225'' 228-228''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           296, 296''


 sonedenosonum
 sonedenoson               2-[2-(4-chlorophenyl)ethoxy]adenosine

 sonédénoson               2-[2-(4-chlorophényl)éthoxy]-9-β-D-ribofuranosyl-9H-purin-6-amine

 sonedenosón               2-[2-(4-clorofenil)etoxi]adenosina




74
WHO Drug Information, Vol. 24, No. 1, 2010                                                                  Recommended INN: List 63


                                             C18H20ClN5O5

                                                                                  NH2
                                             Cl                                             N
                                                                             N

                                                                         O        N         N

                                                                    HO
                                                                                   O




                                                                               OH      OH



 sothrombomodulinum alfa #
 sothrombomodulin alfa                       soluble mutated human thrombomodulin
                                             [388-leucine(M>L),456-glycine(R>G),457-glutamine(H>Q),474-
                                             alanine(S>A)]human thrombomodulin (fetomodulin, CD141)-(4-490)-
                                             peptide, glycosylated

 sothrombomoduline alfa                      thrombomoduline humaine soluble mutée
                                             [388-leucine(M>L),456-glycine(R>G),457-glutamine(H>Q),474-
                                             alanine(S>A)]thrombomoduline humaine (fétomoduline, CD141)-
                                             (4-490)-peptide, glycosylée

 sotrombomodulina alfa                       trombomodulina humana soluble mutada
                                             [388-leucina(M>L),456-glicina(R>G),457-glutamina(H>Q),474-
                                             alanina(S>A)]trombomodulina humana (fetomodulina, CD141)-
                                             (4-490)-péptido, glicosilado

                                             C2181H3278N616O706S49

                                             EPQPGGSQCV         EHDCFALYPG       PATFLNASQI         CDGLRGHLMT        VRSSVAADVI          50
                                             SLLLNGDGGV         GRRRLWIGLQ       LPPGCGDPKR         LGPLRGFQWV        TGDNNTSYSR          100
                                             WARLDLNGAP         LCGPLCVAVS       AAEATVPSEP         IWEEQQCEVK        ADGFLCEFHF          150
                                             PATCRPLAVE         PGAAAAAVSI       TYGTPFAARG         ADFQALPVGS        SAAVAPLGLQ          200
                                             LMCTAPPGAV         QGHWAREAPG       AWDCSVENGG         CEHACNAIPG        APRCQCPAGA          250
                                             ALQADGRSCT         ASATQSCNDL       CEHFCVPNPD         QPGSYSCMCE        TGYRLAADQH          300
                                             RCEDVDDCIL         EPSPCPQRCV       NTQGGFECHC         YPNYDLVDGE        CVEPVDPCFR          350
                                             ANCEYQCQPL         NQTSYLCVCA       EGFAPIPHEP         HRCQLFCNQT        ACPADCDPNT          400
                                             QASCECPEGY         ILDDGFICTD       IDECENGGFC         SGVCHNLPGT        FECICGPDSA          450
                                             LAGQIGTDCD         SGKVDGGDSG       AGEPPPSPTP         GSTLTPP                               487

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Total 23 disulfide bridges in the molecule, so far only four disulfide bridge positions verified.
                                             23 ponts disulfure au total dans la molécule, pour le moment, seuls quatre ont été vérifiés.
                                             23 puentes disulfuro en el total en la molécula, por el momento, sólo cuatro han sido verificados.
                                             9-14      31-146    154-203      224-235

                                             N-Glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             Asn-26 Asn-95 Asn-361 Asn-388




 tafamidisum
 tafamidis                                   2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

 tafamidis                                   acide 2-(3,5-dichlorophényl)-1,3-benzoxazole-6-carboxylique

 tafamidis                                   ácido 2-(3,5-diclorofenil)-1,3-benzoxazol-6-carboxílico




                                                                                                                                                  75
Recommended INN: List 63                                     WHO Drug Information, Vol. 24, No. 1, 2010


                           C14H7Cl2NO3

                           Cl
                                             N

                                             O               CO2H
                           Cl



 taliglucerasum alfa #
 taliglucerase alfa        L-glutamyl-L-phenylalanyl-[495(497)-L-histidine(R>H)]human
                           glucosylceramidase (beta-glucocerebrosidase) peptide with
                           L-aspartyl-L-leucyl-L-leucyl-L-valyl-L-aspartyl-L-threonyl-L-methionine,
                           glycosylated peptide 1-506

 taliglucérase alfa        L-glutamyl-L-phénylalanyl-[495(497)-
                           L-histidine(R>H)]glucosylcéramidase    humaine (bêta-
                           glucocérébrosidase) peptide avec la L-aspartyl-L-leucyl-L-leucyl-
                           L-valyl-L-aspartyl-L-thréonyl-L-méthionine, peptide 1-506 glycosylé

 taliglucerasa alfa        L-glutamil-L-fenilalanil-[495(497)-L-histidina(R>H)]glucosilceramidasa
                           humana (beta-glucocerebrosidasa) péptido con la L-aspartil-L-leucil-
                           L-leucil-L-valil-L-aspartil-L-treonil-L-metionina, péptido 1-506
                           glicosilado

                           C2580H3918N680O727S17

                           EFARPCIPKS      FGYSSVVCVC       NATYCDSFDP       PTFPALGTFS       RYESTRSGRR       50
                           MELSMGPIQA      NHTGTGLLLT       LQPEQKFQKV       KGFGGAMTDA       AALNILALSP       100
                           PAQNLLLKSY      FSEEGIGYNI       IRVPMASCDF       SIRTYTYADT       PDDFQLHNFS       150
                           LPEEDTKLKI      PLIHRALQLA       QRPVSLLASP       WTSPTWLKTN       GAVNGKGSLK       200
                           GQPGDIYHQT      WARYFVKFLD       AYAEHKLQFW       AVTAENEPSA       GLLSGYPFQC       250
                           LGFTPEHQRD      FIARDLGPTL       ANSTHHNVRL       LMLDDQRLLL       PHWAKVVLTD       300
                           PEAAKYVHGI      AVHWYLDFLA       PAKATLGETH       RLFPNTMLFA       SEACVGSKFW       350
                           EQSVRLGSWD      RGMQYSHSII       TNLLYHVVGW       TDWNLALNPE       GGPNWVRNFV       400
                           DSPIIVDITK      DTFYKQPMFY       HLGHFSKFIP       EGSQRVGLVA       SQKNDLDAVA       450
                           LMHPDGSAVV      VVLNRSSKDV       PLTIKDPAVG       FLETISPGYS       IHTYLWHRQD       500
                           LLVDTM                                                                              506

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           6-18 20-25

                           Glycosylation sites N / Sites de glycosylation N / Posiciones de glicosilación N
                           Asn-21 Asn-61 Asn-148 Asn-272

                           α-Man→6−                      R→6−
                                                                 β-Gl-N→peptide
                           α-Man→3− β-Man→4-β-Gl-N→4−

                                R'→2−        R = α-Fuc or H ; R' = β-Xyl or H

                            Fuc = 6-deoxy-D-galactopyranosyl
                            Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl
                            Man = D-mannopyranosyl
                            Xyl = D-xylopyranosyl




 tecarfarinum
 tecarfarin                1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-
                           2H-chromen-3-yl)methyl]benzoate

 técarfarine               4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoate de
                           1,1,1,3,3,3-hexafluoro-2-méthylpropan-2-yl

 tecarfarina               4-[(4-hidroxi-2-oxo-2H-cromen-3-il)metil]benzoato de
                           1,1,1,3,3,3-hexafluoro-2-metilpropan-2-ilo




76
WHO Drug Information, Vol. 24, No. 1, 2010                                                        Recommended INN: List 63


                                             C21H14F6O5

                                                                       O       CH3
                                                     O       O                          CF3
                                                                           O
                                                                                   CF3


                                                     OH



 teglarinadi chloridum
 teglarinad chloride                         4-({N'-[6-(4-chlorophenoxy)hexyl]}-N''-cyanocarbamimidamido)-
                                             1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadecyl)pyridin-1-ium chloride

 chlorure de téglarinad                      chlorure de 4-({N'-[6-(4-chlorophénoxy)hexyl]}-
                                             N''-cyanocarbamimidamido)-1-(3-oxo-2,4,7,10,13,16-
                                             hexaoxaheptadécyl)pyridin-1-ium

 cloruro de teglarinad                       cloruro de 4-({N'-[6-(4-clorofenoxi)hexil]}-N''-cianocarbamimidamido)-
                                             1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadecil)piridin-1-io

                                             C30H43Cl2N5O8
                                                                                                      Cl        O
                                                                                   NC
                                                                                         N             N    O       O
                                                          O
                                                                                    N         N
                                                                                    H         H
                                             Cl                        H3C                    O                 O
                                                                               O                       O



 teprotumumabum #
 teprotumumab                                immunoglobulin G1-kappa, anti-[Homo sapiens insulin-like growth
                                             factor 1 receptor (IGF1R, IGF-1R, IGF-1 receptor, CD221)], Homo
                                             sapiens monoclonal antibody;
                                             gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-33*01
                                             (91.80%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*01 (119-448)],
                                             (221-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-
                                             KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.10] (1'-108') -
                                             IGKC*01 (109'-215')]; (227-227'':230-230'')-bisdisulfide dimer

 téprotumumab                                immunoglobuline G1-kappa, anti-[Homo sapiens récepteur du
                                             facteur de croissance 1 analogue à l'insuline (IGF1R, IGF-1R,
                                             récepteur de l'IGF-1, CD221)], Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-448) [Homo sapiens VH (IGHV3-33*01
                                             (91.80%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*01 (119-448)],
                                             (221-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.10] (1'-
                                             108') -IGKC*01 (109'-215')]; dimère (227-227'':230-230'')-bisdisulfure

 teprotumumab                                inmunoglobulina G1-kappa, anti-[receptor del factor de crecimiento
                                             insulínico tipo 1 de Homo sapiens (IGF1R, IGF-1R, receptor deI GF-
                                             1, CD221)], anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-448) [Homo sapiens VH (IGHV3-33*01
                                             (91.80%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*01 (119-448)],
                                             (221-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.10] (1'-
                                             108') -IGKC*01 (109'-215')]; dímero (227-227'':230-230'')-bisdisulfuro




                                                                                                                        77
Recommended INN: List 63                                          WHO Drug Information, Vol. 24, No. 1, 2010


                                C6476H10012N1748O2000S40

                                Heavy chain / Chaîne lourde / Cadena pesada
                                QVELVESGGG VVQPGRSQRL SCAASGFTFS                  SYGMHWVRQA       PGKGLEWVAI        50
                                IWFDGSSTYY ADSVRGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYFCAREL       100
                                GRRYFDLWGR GTLVSVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                Light chain / Chaîne légère / Cadena ligera
                                EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                ASKRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSKWPPWTFG 100
                                QGTKVESKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                GLSSPVTKSF NRGEC                                                              215

                                Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                Intra-H 22-96 145-201              262-322  368-426
                                         22''-96'' 145''-201'' 262''-322'' 368''-426''
                                Intra-L 23'-88'      135'-195'
                                         23'''-88''' 135'''-195'''
                                Inter-H-L 221-215' 221''-215'''
                                Inter-H-H 227-227'' 230-230''

                                N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                298, 298''


 tipapkinogenum sovacivecum #
 tipapkinogene sovacivec        an attenuated recombinant vaccinia viral vector (derived from the
                                Modified Virus Ankara clone 33.1, MVATG33.1) containing an
                                approximately 168 kilobasepair DNA genome encoding itself, human
                                interleukin-2 (IL-2) and mutated-forms of the Human Papilloma Virus
                                16 (HPV-16) E6 and E7 antigens

 tipapkinogène sovacivec        vecteur viral de la vaccine recombinant atténué (dérivé du virus
                                modifié Ankara clone 33.1, MVATG33.1) contenant un génome ADN
                                d'aproximativement 168 kilopaires de bases se codifiant lui-même,
                                l'interleukine 2 humaine (IL-2) et des formes mutées du
                                papillomavirus humain 16 (HPV-16) et les antigènes E6 et E7

 tipapkinogén sovacivec         vector viral vaccinia recombinante atenuado (derivado del Virus
                                Modificado Ankara clon 33.1, MVATG33.1) contiene un DNA
                                genómico de aproximadamente 168 kilopares de bases que
                                codifican el propio virus, interleukina-2 (IL-2) humana y formas
                                mutadas del Virus del papiloma humano 16 (HPV-16) y los
                                antígenos E6 y E7


 varfollitropinum alfa #
 varfollitropin alfa            [alpha,83-L-asparagine;beta,55-L-asparagine,57-L-threonine]
                                follitropin alpha (human) modified human follicle-stimulating
                                hormone:
                                heterodimer of [83-L-asparagine(H>N)]human glycoprotein
                                hormones alpha chain (FSH-alpha) and [55-L-asparagine(E>N),
                                57-L-threonine(V>T)]human follitropin subunit beta (FSH-beta),
                                glycosylated

 varfollitropine alfa           [alpha,83-L-asparagine;bêta,55-L-asparagine,57-L-thréonine]
                                follitropine alpha (humaine) hormone stimulante du follicule de De
                                Graaf humaine modifiée :
                                hétérodimère constitué de la [83-L-asparagine(H>N)]chaîne alpha de
                                la glycoprotéine des hormones humaines (FSH-alpha) et de la
                                [55-L-asparagine(E>N),57-L-thréonine(V>T)]sous-unité bêta de la
                                follitropine humaine (FSH-bêta) glycosylées


78
WHO Drug Information, Vol. 24, No. 1, 2010                                                             Recommended INN: List 63


 varfolitropina alfa                         [alfa,83-L-asparagina;beta,55-L-asparagina,57-L-treonina] folitropina
                                             alfa (humana) hormona estimulante del folículo de De Graaf humana
                                             modificada :
                                             heterodímero constituido por la [83-L-asparagina(H>N)]cadena alfa
                                             de la glicoproteína de las hormonas humanas (FSH-alfa) y de la
                                             [55- L-asparagina(E>N),57-L-treonina(V>T)]subunidad beta de la
                                             folitropina humana (FSH-beta) glicosiladas

                                             C971H1511N267O306S26

                                             Alpha subunit / Sous-unité alpha / Subunidad alfa
                                             APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ 50
                                             KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACNCSTCYYH KS         92

                                             Beta subunit / Sous-unité bêta / Subunidad beta
                                             NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
                                             CTFKNLTYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100'
                                             PSYCSFGEMK E                                           111'

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             7-31 10-60 28-82 32-84 59-87
                                             3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'

                                             N-Glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             Asn-7' Asn-24' Asn-55' Asn-52 Asn-78


 velusetragum
 velusetrag                                  N-{(1R,3r,5S)-8-[(2R)-2-hydroxy-
                                             3-(N-methylmethanesulfonamido)propyl]-8-azabicyclo[3.2.1]octan-
                                             3-yl}-2-oxo-1-(propan-2-yl)-1,2-dihydroquinoline-3-carboxamide

 vélusétrag                                  N-{(1R,3r,5S)-8-[(2R)-2-hydroxy-
                                             3-(N-méthylméthanesulfonamido)propyl]-8-azabicyclo[3.2.1]octan-
                                             3-yl}-2-oxo-1-(propan-2-yl)-1,2-dihydroquinoline-3-carboxamide

 velusetrag                                  N-{(1R,3r,5S)-8-[(2R)-2-hidroxi-3-(N-metilmetanosulfonamido)propil]-
                                             8-azabiciclo[3.2.1]octan-3-il}-2-oxo-1-(propan-2-il)-
                                             1,2-dihidroquinolina-3-carboxamida

                                             C25H36N4O5S

                                                 H3C        CH3

                                                        N       O
                                                                    H H
                                                                    N              H
                                                                                    H OH CH3
                                                                O                N       N   CH3
                                                                                           S
                                                                             H                     O O

 zaurategrastum
 zaurategrast                                (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-
                                             3-{4-[(2,7-naphthyridin-1-yl)amino]phenyl}propanoic acid

 zauratégrast                                acide (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-én-1-yl)amino]-
                                             3-[4-(2,7-naphtyridin-1-ylamino)phényl]propanoïque

 zaurategrast                                ácido (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-il)amino]-
                                             3-{4-[(2,7-naftiridin-1-il)amino]fenil}propanoico




                                                                                                                                           79
 Recommended INN: List 63                                                 WHO Drug Information, Vol. 24, No. 1, 2010


                                                  C26H25BrN4O3

                                                                          H
                                                                          N    N


                                                   O
                                                                 H
                                                                     OH   N
                                                            N
                                                    Br      H
                                                                 O




 #   Electronic structure available on Mednet: http://mednet.who.int/
 #   Structure électronique disponible sur Mednet: http://mednet.who.int/
 #   Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 80
